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ABSTRACT
Metallothionein Isoform 3 Expression in human Bladder Urothelium
Seongmi Park
The third isoform of methallothionein, MT-3 is shown to have a restricted pattern of
tissue distribution with expression confined to the neural tissue. Previous work done by
this laboratory has been shown that MT-3 is not expression in the normal bladder but is
over-expressed in bladder cacer with levels correlating to the type and grade of tumor.
Recently, a new bladder epithelial cell line UROtsa has been characterized that does not
express the MT-3 gene and may serve as a useful in vitro model system of the normal
human urothelium. The goal of this study was to see the effect of MT-3 over expression
in the normal human bladder epithelial cell line. The MT-3 transfected cells expressed the
mRNA for the MT-3 gene but expressed very little MT-3 protein. Treatment with
cadmium or zinc did not increased the level of MT-3 protein in MT-3 transfected clones.
Otherwise MT-1E transfected UROtsa cells showed increased both mRNA and protein
by exposure to cadmium. These data suggests that the MT-1/2 and MT-3 are regulated
different ways. In vitro transformation model systems are very useful tools in the
understanding of fundamental differences between normal cells and tumor cells if both
have been derived from a common source. We showed the malignant transformation of
normal human urothelial cell line by chronic exposure to cadmium or arsenic in vitro.
The malignant transformation of these exposed cells was confirmed by increased growth
rate, anchorage independent growth, and tumor development in nude mouse. The
malignant transformation of normal human urothelial cells is compelling evidence that
arsenic and cadmium have the potential to be human bladder.

ACKNOWLEDEMENTS
The author thanks Dr. Joginder Nath for all support to be educated: Dr. Mary A. Sense,
Dr. Scott H. Garrett, Dr. Seema Somji for all technical helps: Dr. Daniel Pannaccione for
being a committee member. The author thanks especially to Dr. Donald A. Sens for
giving me chance to work with him.

iii

TABLES OF CONTENTS
Abstract …………………………………………………………………………………ii
Acknowledgements …………………………………………………… …………….. iii
Table of Contents ……………………………………………………………………….iv
Table of Figures ………………………………………………………… ………………v
Introduction and Review of Literature ………………………………… ………………..1
Materials and Methods ………………………………………………………………….25
The Effect of Metallothionein Isoform 3 Expression in UROtsa Cell Line … ……...….40
In vitro Transformation of UROtsa Cell Line by Chronic Exposure to Arsenic or
Cadmium ……………………………………………………………………………….. 64
Tumorigenicity and Histological Observation of Tumors Produced by Arsenic- or
Cadmium-Transformed Cells in Nude Mouse ……………………………………….….90

iv

TABLE OF FIGURES
Figure 1. Stable overexpression of MT-3 mRNA in UROtsa cells …………….……….43
Figure 2. Expression of MT-3 in 16 MT-3 gene transfected UROtsa clones compared to
other MT-3 gene transfected cell lines ……………………………………..…45
Figure 3. Viability of UROtsa(3.1) and UROtsa(MT3) cells exposed to cadmium
chloride ……………………………………………………………….………47
Figure 4. Expression of metallothionein isoforms in UROtsa(3.1) cells exposed to
cadmium chloride ………………………………………………………….…48
Figure 5. Expression of metallothionein isoforms in UROtsa(MT3) cells exposed to
cadmium chloride ………………………………………………………….… 49
Figure 6. Expression of metallothionein-3 in UROtsa(MT3) cells exposed to cadmium
Chloride ……………………………………………………………..…….…..50
Figure 7. Expression of metallothionein-1/2 in UROtsa(3.1) (A) and UROtsa(MT3) (B)
cells exposed to cadmium chloride …………………………………………..51
Figure 8. Viability of UROtsa(3.1) (A) and UROtsa(MT3) (B) cells exposed to zinc ...53
Figure 9. Expression of metallothionein-1/2 protein in UROtsa(3.1) (A) and
UROtsa(MT3) (B) cells exposed to zinc ……………………………..………54
Figure 10. Expression of metallothionein-3 in UROtsa(3.1) (A) and UROtsa(MT3) (B)
cells exposed to zinc …………………………………………………….….55
Figure 11. Stable overexpression of MT-1E mRNA in UROtsa cells …………...…..…56
Figure 12. Viability of UROtsa(MT1E) cells exposed to cadmium chloride ………..…57
Figure 13. Effect of cadmium on MT-1/2 protein expression in URO(MT1E) cells…...58
Figure 14. Phase contrast photomicrographs of human urothelial cell line ………...…..68
Figure 15. The effect of cadmium or arsenic exposure to UROtsa cell growth ……..…71
Figure 16. Effects of arsenic or cadmium exposure to UROtsa cell in colony formation
assay ……………………………………………………………..……...…..74
v

Figure 17. Colony-formation capacity of UROtsa cells …………………… ……...…75
Figure 18. Expression of metallothionein protein in UROtsa cells …………………….77
Figure 19. Tumorigenicity of arsenic or cadmium exposed UROtsa cells in nude
mice ………………………………………………………………………....93
Figure 20. Histological analysis of tumors produced by heterotransplatation of cadmiumtransformed UROtsa cells with serum into nude mice………………………95
Figure 21. Histological analysis of tumors produced by heterotransplatation of cadmiumtransformed UROtsa cells without serum into nude mice………….……… 97
Figure 22. Histology (H&E staining) of tumors produced by heterotransplantation of
arsenic-transformed UROtsa cells with serum into nude mice ……...……..98
Figure 23. Histology of tumors produced by heterotransplantation of arsenic-transformed
UROtsa cells without serum into nude mice ………………………...……..101
Figure 24. Histology of tumors produced by human prostate cells injected nude
mice…………………………………………………...……………………..101
Table 1. Effect of exposure to arsenic or cadmium on doubling time of UROtsa cells ...72
Table 2. Tumorigenicity of arsenic or cadmium exposed UROtsa cells in nude mice….94

vi

INTRODUCTION AND REVIEW OF LITERATURE

1

METALLOTHIONEIN
Metallothionein (MT) was discovered in 1957 as a cadmium–binding protein
from equine kidney cortex (1). The metallothioneins are present in a broad range of
organisms from a few prokaryotes to all eukaryotic species from yeasts, flies, plants
and vertebrates. The definition of metallothioneins is cysteine rich low molecular
weight (6 to 7kDa) nonenzymatic metalloproteins or metallopeptides with a high
affinity for heavy metals (2). The metallothioneins are divided into three classes
based on structural criteria. Class I metallothioneins are metalloproteins with the
cysteine residues arranged as Cys-X-Cys and their nucleotide sequences are highly
conserved. Class I includes all MTs found in vertebrates including mammals and
some invertebrates such as crustaceans and mollusks. Class II metalloproteins are
found in unicellular eukaryotes such as yeasts, and their primary structure has no CysX-Cys structures like class I. Class III, present in plants, is a nontranslationally
synthesized metal thiolate polypeptide and known as phytochelatin with atypical
gamma-glutamylcysteinly units.
Based on small differences in sequence and charge characteristics, mammalian
MTs can be divided into four groups from MT-1 to MT-4. The structures of all four
isoforms are highly conserved at the amino acid sequence level and are consisted of
three exons and two introns. The mammalian MTs are 61-68 amino acid peptides
containing 20 cysteines, 6-8 lysines, 7-10 serines, and a single acetylated methionine
at the amino terminus (3). The most unique characteristic of MT is the recurrence of
Cys-X-Cys tripeptide sequences where X is for any amino acid residue except
2

cysteine and aromatic amino acids. The sulfur atoms of 9 cysteines from N- terminal
beta domain and 11 cysteines from C-terminal alpha domain provide cooperative
binding sites for various transitional metals including zinc and cadmium (2).
Therefore, each MT protein binds 7-10 g atoms of metal/mol MT, up to three metals
in alpha domain and four metals in beta domain. Because metals stabilize the
secondary structure of protein, loss of metal causes structural changes. It makes them
susceptible to proteolysis.
In the mouse, there are four MT genes that reside in a 50-kb region on
chromosome 8 without any pseudogenes. In contrast, the human MT genes are more
complicated. The human MT-1 and MT-2 genes are encoded by a multigene family
that likely doubled as a result of a gene duplication event that occurred between the
time of divergence of rodents and humans. The human MT genes are clustered at a
single locus on chromosome 16(16q13) and consist of 10 functional isoform (MT-1A,
MT-1B, MT-1E, MT-1F, MT-1G, MT-IH, MT-X, MT-2A, MT-3 and MT-4) and 7
nonfunctional isoforms( MT-1C, MT-1D, MT-1I, MT-1J, MT-1K, and MT2-B) (4-6).
The existence of multiple MT-1 and MT-2 isoform genes raises the possibility that
isoforms may have different roles and be regulated differently in humans. For
example, metals induce all MT-1 and MT-2 isoforms whereas glucocorticoids only
induce MT-2A and MT-1E in human (7). Whether there are distinct functions for
each of the human MT isoforms or whether they merely represent a duplication of
function has not yet been established.
The common MT isoforms, MT-1 and MT-2, differ by only one single negative
3

charge and have been studied extensively. They consist of 61-62 amino acids and
exhibit a ubiquitous pattern of tissue distribution, show high levels in the liver and
kidney, and are highly inducible by various stimuli including metals, hormones,
cytokines and physical and chemical stresses (8). When cells are exposed to heavy
metals such as cadmium, the amount of MT-1 and MT-2 proteins are elevated from
several to hundreds times higher due to increased rates of transcription. The dramatic
inducibility of metallothioneins by heavy metals makes promoters of MT-1 and MT-2
genes excellent candidates to be used to control expression of a fusion gene via an
exogenous metal supply (9). The MT-3 and MT-4 isoforms were only recently
discovered and are subjects of more limited studies. MT-4, the most recently
identified isoform, with 62 amino acids, is present in the stratified squamous
epithelium of skin, tongue, and intestinal lining and may be involved in the
differentiation of these tissues (10). MT-3, a brain-specific MT isoform, was isolated
from the normal human brain extract but was deficient in brains of patients with
Alzheimer (11, 12). Decreased MT-3 protein in Alzheimer’s patients suggested that
MT-3 may suppress brain neurotropic activity. MT-3 is predominantly expressed in
neurons of the central nerve system, although recently published papers demonstrate
that it is also detected in reproductive organ tissues, tongue, stomach, heart and
kidney (13, 14). The human MT-3 contains 68 amino acids and shows around 64 %
identity with human MT-1 and MT-2. The growth inhibitory activity of the MT-3 is
abolished by a double mutation within the beta domain resulting in the conversion of
the C-P-C-P sequence to either C-S-C-A or C-T-C-T. This proline-rich region in the
4

N-terminal beta domain of MT-3 may have growth inhibitory activity that other
metallothionein isoforms do not have (15). When transfected into baby hamster
kidney cells, MT-3 gene but not MT-1 gene showed inhibition of cellular
proliferation under conditions of zinc deficiency. The discovery of growth inhibitory
activity of MT-3 was the first indication that different MT isoforms may have
different functions. MT-3 knockout mice show reduced zinc content in brain and are
more sensitive to seizure-induced injury, whereas mice overexpressing MT-3 are
resistant to this damage and kainic acid toxicity (16).
The biosynthesis of metallothionein is controlled by complex processes. Studies
of MT gene structure and regulation have been focused on mouse MT genes because
of their simplicity. Several studies demonstrate that MT genes are inactive in some
cells as a consequence of DNA methylation (17). In cells or plants selected for
resistance to cadmium, enhanced expression of MT protein can also be achieved
through amplified copies of MT gene (18, 19). The MT genes in most cells are
mainly controlled at the transcriptional level by various inducers (20). In general, MT
genes have several cis-acting response elements, including metal response elements
(MREs), a TPA-responsive element, a cyclic AMP responsive element, and an
interferon responsive element. Two proteins were identified from nuclear extracts of
HeLa cells as trans-acting elements for metal-mediated MT gene transcription. The
MRE-binding protein (MREBP) binds MREs of the human MT-2A for inhibiting MT
gene transcription. The MRE-binding transcription factor (MTF-1) is a constitutively
active zinc-sensitive transcription factor. MTF-1 may bind to multiple copies of metal
5

response elements (MREs) in the promoter region of an MT gene and elevate MT
gene transcription rates (21). However, MT-3 and MT-4 are less or not responsive to
inducers and have a more restricted pattern of expression. The MT protein level is
also regulated by protein degradation. Several studies showed that half–life of MT
protein also depends on the age of the animals and the type of metal bound to MT
(22). The degradation of MT occurs in both cytoplasm and lysosomes. A in vitro
study demonstrated that low pH increased the rate of metal release from MT. For
example, zinc is fully released from MT at pH 4. The lysosomes are acidic with a pH
range of between 3.6 and 5, resulting in zinc dissociation from MT. Several proteases
including serine protease and trypsin digest MT partially in vitro. Some proteases
including acidic proteases and cathepsin B are involved with MT degradation in
lysosomes (23). The degradation rate of MT increases when MT binds less than five
atoms of metal (24). The degradation of MT protein is primarily regulated by cellular
zinc content, and apo-MT is more susceptible to degradation than metal-occupied MT
(25).
Even though amino acid sequences of MT proteins are highly conserved and
expressed from prokaryotic to eukaryotic organisms, biological functions of the MTs
are still controversial (26). The large number of factors that stimulate the biosynthesis
of MT makes it difficult to pinpoint a specific biological role. The understanding of
the functions of MTs has been focused on their roles in heavy metal detoxification
because of their metal binding ability. Numerous in vivo and in vitro studies have
confirmed the protective function of MTs against heavy metal toxicity (27). The MTnull
6

mice showed an increased sensitivity to cadmium–induced renal injury and
hepatotoxicity after chronical exposure to cadmium (28). In contrast, transgenic mice
that carry 56 copies of the MT-1 gene showed resistance against cadmium lethality
and hepatotoxicity (29).
The MTs also are considered as cellular storage sites for homeostasis of essential
metals such as zinc and copper during growth and development. Although MTs are
well known for their protection against cadmium, yet when they were isolated from
liver tissue, MTs were predominantly zinc-containing proteins (30). These results
demonstrated that MT binds to zinc and copper under physiological conditions
therefore it might be involved in the metabolism of nutrient metals. Zinc is an
essential participant in many DNA and RNA polymerases and serves as a structural
component of the zinc finger domains in over 300 DNA–binding proteins (8).
Therefore, MT may control function of zinc-dependent proteins by acting as both zinc
donor and an acceptor. MTs may function as potent scavengers of free radicals
because of their high cysteine content. The role of MTs as antioxidants was suggested
in MT-1 and MT-2 knock out cell studies. It was shown by Lazo and coworkers that
MT null cells were more sensitive to tert-butyl hydroperoxide-induced oxidative
stresses (31).
The experiment with MT-1/2 double knockout mice was disappointing because
these MT–null mice were normal under the standard laboratory condition except for
their higher susceptibility to heavy metal toxicity and UV-irradiation, and higher
sensitivity to changes in dietary zinc content during development, indicating that MT
7

is not essential for life. The MTs are also not essential for protection from oxidative
stress except under extreme conditions. Glutathione and other gamma-glutamyl
compounds are the major cellular non-protein thiol-containing reductants that protect
cells against oxidative stress and detoxification of xenobiotics and may represent an
integral part of the toxic response of some heavy metals (32). The glutathione appears
to be the first line of defense against cadmium toxicity preceding MT induction.
Although glutathione and MT show similar detoxification and anti-oxidation
functions in vivo, mice can survive without MT but not without glutathione.
If the function of MTs is limited to protection from cellular toxicity, it would be
expressed to be expressed only after exposure to toxic heavy metals and other
environmental stresses but in fact the basal level of MT proteins is relatively high.
MTs are also induced not only by a variety of metals but also several hormones,
cytokines, growth factors, and tumor promoters, implying their involvement in
diverse cellular processes (33). Due to overexpression of MT protein in proliferating
cells, various tumors, and developing tissues, it has been suggested that MT takes part
in the control of cellular proliferation and differentiation. The involvement of MT
with zinc metabolism, the requirement of zinc during G1 to S phase and transient
translocation of MT protein from cytoplasm into nucleus during cell proliferations
lead to possible link between MT and cancer (34). The levels of MT expression have
been investigated in a wide variety of tumors. Although MTs appear in various
human tumors, the expression of MT is not universal to all tumors. The presence of
MT may depend on the type of tumor, the cellular origin, the morphological
8

heterogeneity, or the stage of growth (35). The MTs could be found at high levels in
the nucleus and in the cytoplasm in both benign and malignant tumors. It has been
shown that the incidence of apoptosis decreases with increasing immunoreactivity of
MT staining (36). However, in some tumor types such as colonic carcinoma, a
correlation between MT overexpression and better prognosis has been found (37).
Otherwise MT-1 and MT-2 overexpression appears to be associated predominantly
with more malignant, higher – grade tumors in ductal breast cancer (38), prostate
cancer (39), skin carcinoma, melanomas (40), cervical cancer (41), acute
lymphoblastic leukemia (42), and pancreatic carcinomas (43). Several studies
demonstrated that MT-1 and MT-2 also are overexpressed in bladder cancer (44). The
intensity of MT-1 and MT-2 staining is correlated with bladder tumor grade, with the
highest–grade tumors having the more intense MT protein.
The resistance of certain tumors to anticancer drugs is one of the major problems
in cancer chemotherapy. Various defense mechanisms against anticancer drugs by
cancer cells include increased expression of multidrug resistance gene, decreased
drug accumulation or increased DNA repair activity. Another suggested mechanism
is the protection of targeted macromolecules by increased cellular thiols such as
glutathione or MT. MT was considered as one of the anticancer drug-resistance
molecules because of high cysteine content and alkylating agent binding ability and
induced MT synthesis by alkylating agents (45). The acquisition of drug resistance
has been recognized after exposure to anticancer drugs. The increased expression of MT
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in certain tumors is associated with resistance to chemotherapeutic agents. Many
clinically used anticancer agents are electrophilic, and generate DNA inter- and
intrastrand cross-links. Cisplatin–based chemotherapy has been widely used to treat
patients with metastatic and locally advanced carcinoma of the bladder for more than
two decades (46). Cisplatin is one of the most potent cytotoxic drugs in chemotherapy
and ameliorates numerous tumors. Cistplatin also is a common chemotherapeutic
agent for solid tumors, including testicular carcinomas, ovarian cancer, cancer of the
head and neck and small cell lung carcinomas (47). Cisplatin causes intrastrand DNA
crosslinking, thereby disrupting DNA and RNA synthesis (48). Nevertheless,
resistance to cisplatin is a problem that is encountered in the chemotherapy of
urologic tumors, especially transitional cell carcinomas. The overexpression of MT in
bladder tumors was found in several studies that had failed cisplatin chemotherapy
(49, 50).
The immunohistochemical staining demonstrates that overexpresssion of the MT1 and MT-2 protein is correlated with cisplatin resistance in transitional cell
carcinoma of the urinary tract (51). The cells with acquired resistance to heavy metals
overexpress MT and are cross resistant to the alkylating agents. The suggested
mechanism of cisplatin resistance by MT is that a nucleophilic protein, MT, interacts
with electrophilic anticancer drugs such as cisplatimum and cyclophosphamide. MT
binds to cisplatin in the cytoplasm and this complex decreases the intranuclear drug
concentration, thus preventing cisplatin from forming DNA intrastrand adducts (52).
There also is considerable evidence that some cisplatin-resistant cell lines do not
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show increased MT levels (53). Therefore, MTs may play an important role in
decreased cisplatin toxicity but not critical.
The finding of altered metallothionein expression in bladder cancer is particularly
significant because bladder cancer has a strong association with the environment
pollution. Epidemiological studies dating back to the 19th century showed that bladder
cancer was one of the first cancers recognized as being caused by carcinogens present
in the industrial setting and factory workers (54).
BLADDER CANCER
Bladder cancer is the fourth common cancer among men and eighth among
women (55). In the United States, approximately 54,000 new cases of bladder cancer
and around 12,000 bladder cancer related deaths are reported each year (56).
Although which chemical in smoke is responsible for carcinogenesis is uncertain, a
major factor in the causation of bladder cancer is tobacco usage, with 40-85% of all
bladder cancer cases attributable to smoking cigarettes. Moreover, smokers have a 2
to 10-fold increased risk over nonsmokers for developing bladder tumors (57). A
strong association between cigarette smoking and bladder cancer has also been
defined (58). Smoking is estimated to cause two to fourfold increased risk for bladder
cancer, and estimates maintain that 50 % of bladder cancers would not occur in the
absence of cigarette smoking, with the majority of the remaining bladder cancers
being caused by industrial or agricultural carcinogens.
The mammalian urinary bladder, a dynamic reservoir for urine, expands and
contracts depending on the volume contained within. The mammalian bladder wall is
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composed of serous layer, muscular wall and transitional epithelium. The transitional
epithelium, urothelium, exhibits unique structural characteristics associated with its
specialized role as a permeability barrier and accommodating tissue structure. The
urothelia are subdivided into basal cells, intermediate cells and squamous cells.
Clinical bladder cancers are heterogeneous in their growth behavior and
histopathological subtypes, which include transitional cell carcinoma (TCC),
squamous cell carcinoma, and adenocarcinoma. TCC, which makes up 90 % of all
bladder cancer cases, is associated with cigarette smoking and occupational and
environmental chemical exposures. Squamous cell carcinomas are observed in 510 % of all bladder cancer cases and are associated with chronic irritation of the
bladder mucosa. Adenocarcinoma is seen around 1-2 % of bladder cancer cases. The
definition of tumor stage and grade is how far the tumor has progressed. The higher
the grade or stage means the worse the cancer. Upon microscopic examination
bladder cancers are divided into the superficial bladder cancer and invasive bladder
cancer based on metastasis. The most common TCC is superficial bladder tumor as a
low grade papillary tumor with relatively benign behavior but high recurrence rate.
Superficial transitional cell carcinoma bladder tumors do not invade lamina propria, a
thin membrane that separates the mucosa of the bladder from the muscle layer. The
muscle invasive carcinoma in situ (CIS) is frequently metastasized and marked as
high grade. Around 10 % of patients with benign tumor eventually develop malignant
disease (59). Over the last 15 years, the annual incidence of bladder cancer has
increased by nearly a third. The incidence of bladder cancer is increasing, and despite
12

advances in chemotherapy, survival rates for invasive bladders have not significantly
improved.
The development of human bladder cancer is a long complex process including
activation and inactivation of cellular genes. Studies with karyotypic analyses in
human bladder cancer tissues and cells showed partial deletion of several
chromosomes and mutations. The cytogenetic and allelic deletion analyses of clinical
samples of human bladder cancers indicate that loss of genes on chromosomes 3p, 6q,
8p, 9q, 11p, 13q, 17p, and 18q may contribute to tumorigenic transformation of
human urothelial cells (13, 60).
CARCINOGENECITY OF ARSENIC AND CADMIUM
Arsenic is a common environmental chemical. In biological systems, inorganic
arsenic exists as either arsenate (As5+) or arsenite (As3+). Arsenic in drinking water is
predominantly inorganic and highly toxic. Inorganic arsenic is detoxified through
methylation and then methylated arsenicals are eliminated via the urine (61). The
primary concern for chronic exposure of human populations to arsenic by inhalation
exposure and contaminated drinking water is its carcinogenic potential. Although
animal studies do not provide any evidence of carcinogenesis of arsenic, there is
considerable evidence that arsenic causes cancer in humans. Arsenic is a human
carcinogen and a leading top priority hazard in the United States (62). Although
arsenic is associated with various tumors, including lung, skin, bladder and liver, the
mechanism of arsenic carcinogenesis is still unclear (63). Cadmium is a common
environmental toxic material. Acute exposure to cadmium produces hepatic,
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pulmonary, and testicular injury, whereas chronic exposure results in renal and bone
injury and cancer, as well as toxicity to other organs. Even though cadmium is
officially classified as a carcinogen by International Agency for research on Cancer
(IARC) based on animal studies, the molecular mechanism of cadmium-induced
carcinogenesis remains controversial (64). Recent reports have demonstrated the
malignant transformation of immortalized cell lines by continuous exposure to heavy
metals (65, 66). These trials are useful for better understanding of heavy metalinduced
transformational mechanisms.
OBJECTIVES OF THIS STUDY
This laboratory’s interest in MT-3 originated from recent observations that MT-3
was overexpressed in all human bladder cancers, but was not expressed in normal
urothelial cells (67). The level of MT-3 expression correlated to the grade of the
bladder cancer and was elevated in dysplastic lesions. These features suggested that
MT-3 might be developed as a biomarker for human bladder cancer. Recently, a new
cell culture model of human urothelium was developed by this laboratory through
altering the growth medium formulation of the previously isolated UROtsa cell line
from a serum-containing to a serum-free medium (68, 69). UROtsa cells maintained
in serum-free medium have several morphological features of transitional epithelium
of the urinary bladder including a multilayered appearance and apical location of
umbrella-like cells which exhibit tight junctions. These cells also have a basal
expression pattern of MT similar to that observed in in situ urothelium. The UROtsa
cell line does not express the MT-3 gene and may serve as a useful in vitro system for
14

the normal human urothelium for this study.
The first aim of these studies was to determine if there is a functional
consequence of forcing MT-3 overexpression onto the MT-3 null background known
to exist in the normal urothelial cell. In chapter three, the UROtsa cell line was stably
transfected with MT-3 cDNA under control of the cytomegalovirus (CMV) promoter
and the effect of MT-3 overexpression in the UROtsa cell line was demonstrated.
Heavy metal exposure was chosen for induction of MT gene expression and two
metals having diverse exposure patterns in human were studied: cadmium, an
environmental pollutant, and zinc, a nontoxic essential trace element.
The second goal of the study was to determine transformational ability of
cadmium or arsenic on the UROtsa cell line. Recently the carcinogenic effect of
cadmium and arsenic was reported, but the molecular mechanism of carcinogenesis is
not clear (70, 71). In chapter four, UROtsa cells were cultured with cadmium or
arsenic for up to 10 months. The possibility of transformation of these UROtsa cells
was tested by measurements of growth rate, a soft agar assay, and tumor formation
after injection into nude mice. The protein samples also were collected during this
period and MT protein levels were measured.
The final goal of these studies was to assess the role of MT in cadmium or arsenic
induced carcinogenesis. Even though MT was overexpressed in several human
tumors, the functional role of MT in protection of tumor cell growth is poorly
understood. In chapter five, histological observations of nude mice that were injected
by transformed UROtsa cells were performed. The expression of MT was also tested
15

by immunohistochemistry.
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Cell Culture
The UROtsa cells were cultured as previously described (1). Stock cultures of
UROtsa cells were grown in T 75 flasks (Corning, Cat No.430720) in 15 ml of regular
medium or serum-free medium. The regular medium is Dulbecco’s modified Eagles’
medium (DMEM, Gibco-BRL Cat No 31600-75) with 5 % serum (Hyclone Laboratories,
Cat No SH30070-03). The serum-free medium is composed of a 1:1 mixture of DMEM
and Ham’s F-12 (Gibco-BRL Cat No 21700-109) supplemented with selenium
(Collaborative Biomed Cat No 40201, 5 ng/ml), insulin (Collaborative Biomed Cat No
40310, 5 µg/ml), transferrin (Collaborative Biomed Cat No 40204, 5 µg/ml),
hydrocortisone (Sigma Cat No H0135, 36.4 ng/ml), triiodothyronine (Sigma Cat No
T5516, 4 pg/ml) and epidermal growth factor (Gibco-BRL Cat No 13247-051, 10 ng/ml).
The medium was filtered and kept at 4OC. The serum-free medium was kept for only one
week at 4OC . UROtsa cells were fed fresh growth medium every three days, and at
confluence (normally 6-12 days post subculture), the cells were subcultured at a 1:4 ratio
using 0.05 % trypsin-0.02 % EDTA (Gibco-BRL Cat No 25300-062). To subculture
UROtsa cells, cells were washed with PBS. After removal of PBS, 5 ml Typsin-EDTA
was added to the cells. The T75 flask was incubated on 37 OC warm plate until cells were
detached. The cell suspension was collected into 50 ml tube and centrifuged at 1000x
RPM for 5 minutes at room temperature. The cell pellet was resuspended with 4 ml cell
culture medium and transferred 1ml of cell suspension to a new T75 flask.
Stable Transfection of UROtsa Cells
The coding sequence of the human MT-3 gene was obtained from human
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proximal tubule cell RNA by RT-PCR using MT-3 specific primers (2). The RT-PCR
products were blunt-end ligated into the EcoRV site of pcDNA3.1/hygro (+) (Invitrogen,
Carlsbad, CA). The human MT-1E containing pcDNA3.1/hygro (+) plasmid was made
by the same strategy (2). This vector has a cytomegalovirus immediate-early promoter
upstream of the multiple cloning site and a hygromycin B resistance gene driven by an
SV40 early promoter. Fsp I restriction endonuclease which cuts the vector once at the
bacterial amphicillin resistance gene was used to linearize the vector construct before
transfection. The construct was transfected into UROtsa cells using Effectine transfection
reagent (Qiagen, Valencia, CA). The day before transfection, cells were fed with fresh
5 % FBS- Dulbecco’s modified Eagles’ (DME) medium. The parameters of the
transfection were 1:10 plasmid to Effectine and 2 µg DNA per 9.6 cm2 well. Cells (6 µl
of 0.1 µg/µl linearized plasmid, 4.8 µl of enhancer, 6 µl of effectine) were incubated with
the lipid-DNA complexes for 24 hours followed by normal growth medium for 24 hours
at which time the cells were trypsinized and seeded at 10 % confluence for selection in 30
µg/ml hygromycin B. Clones were isolated using cloning rings (Sigma, St. Louis MO)
and propagated in 30 µg/ml of hygromycin B. The stably transfected clones were
identified by MT isoform specific RT-PCR and cultured with serum-free medium for
further investigation.
Exposure to cadmium and zinc
The confluent cells in T75 flasks were fed with fresh serum-free medium 24 hours
prior to subculture. The cells were seeded to 1:4 ratios into six-well plates and fed with 3
ml of fresh media every three days until 80 % confluence. When cells had reached 80 %
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of confluence, they were exposed to cadmium or zinc. The zinc and cadmium were
dissolved in water at a concentration of 0.1 mg/ml, filtered, divided into 1 ml of aliquots
and kept at room temperature. The concentrations of CdCl2 utilized were 1, 5, 9 µM and
those of ZnSO4 were 50 and 100 µM. The cells were fed with fresh growth medium
containing the metals every 72 hours for 16 days. Protein and RNA were collected at the
time points of 6, 12, 24, 36, 48, 72, and 96 hours after exposure to metals. MTT assay
was performed at the same times.
MTT Assay
The MTT assay was performed to assess the cytotoxic effect of cadmium or zinc
on UROtsa cells (3). The cellular viability was determined by measuring the production
of formazan from MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide;
Sigma, Cat No M-5655). MTT was dissolved in DMEM media (5 mg/ml), filtered
through a 0.2 µm Acrodisk filter (Gelman Laboratory, Ref 4192), and kept at -20 OC as 1
ml aliquots. The cells were cultured in six-well plates and 40 µl of 5 mg/ml of MTT
solution was added to each of the six-well plates. After 3.5 hours later in a CO2 incubator,
the cells were rinsed with PBS buffer once and 1ml of acidic propanol (416 µl of abs HCl
in 50 ml isopropanol) was added to each well. After 5 minutes, 200 µl aliquots were
applied in triplicate from each six-well plate and placed in a 96-well plate. The first two
wells of 96-well plate contained 200 µl of acidic propanol as a blank, and the absorbance
of converted dye was measured by a Dynatech MR5000 plate reader (Dynatech Inc.,
Guernsey Channel Islands) at a wavelength of 570 nm with background subtraction of
630 nm.
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Isolation of RNA
Cells were cultured in six-well plates and fed the day before harvesting RNA.
Total RNA was isolated according to the protocol supplied with TRI REAGENT TM
(Molecular Research Center, Inc. Cincinnati, OH). After removal of media, cells were
incubated with 1 ml TRI reagent for 10 minutes at room temperature. All cell lysates
were kept at -70 OC before further investigation. The cell lysates were thawed at room
temperature and added to 0.1 ml BCI reagent. After vortexing for 20 seconds, cell lysates
were kept at room temperature for 15 minutes. After centrifugation at 4 OC for 15
minutes at 12,000xg, the upper aqueous phase was transferred into a new tube. After
adding 0.5 volume of isopropanol, mixtures were incubated at -20 OC overnight.
Mixtures were centrifuge at 4 OC for 15 minutes. The pellets were washed with 70 %
ethanol twice and dried for 10 minutes. Cell pellets were resuspended in 25 µl of RNAfree water and stored at -70 OC. For RNA quantitation, 2 µl RNA solution and 98 µl Tris
buffer (1 mM Tris-HCl, pH 8.0) were mixed thoroughly and read at 260 and 280 nm with
a spectrophotometer. The total RNA was diluted to 0.5 µg RNA / 3 µl dH2O. Before
being used for RT-PCR, RNA solutions were kept at -70 OC.
RT-PCR
Total RNA was diluted to 0.5 µg/ 3 µl with water. Total RNA was reverse
transcribed with random hexanucleotide primers and subjected to PCR using the
Gene/Amp RT-PCR core kit (Applied Biosystems, Forster City, CA) according to the
manufacturer’s protocol. The composition of reverse transcription master mix was 5 mM
MgCl2, 1x PCR Buffer II (50 mM KCl and 10 mM Tris-HCl, pH 8.3), 1 mM dATP, 1
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mM dCTP, 1 mM dTTP, 1 mM dGTP, 2.5 mM random hexamers, 1 U/µl RNase
inhibitor and 2.5 U/µl MuLV reverse transcriptase. Aliquots of 1.5 µl of RNA samples
(0.5 µg/ 3 µl) were placed in sterile PCR reaction tubes on ice. After adding 8.5 µl of
master mix reagents, each reaction tube was gently mixed. The thermocycler (GeneAmp
PCR system 9700, Applied Biosystems) ran for a single cycle of 25 OC for 10 minutes,
42 OC for 20 minutes, 99 OC for 5 minutes. The reverse transcribed product was either
used for PCR or kept at -20OC.
PCR master mix was composed of 2 mM MgCl2, 1x PCR Buffer II, specific upper
and lower PCR primers, and 1.25 U AmliTag DNA polymerase with total 40 µl of
volume with water. Primers for MT-1E were 5’ GCTTGTTCGTCTCACTGGTG 3’, and
5’ CAGGTTGTGCAGGTTGTTCTA 3’ (product size, 284 bp); for MT-1X, 5’
TCTCCTTGCCTCGAAATGGAC 3’, and 5’ GGGCACACTTGGCACAGC 3’ (product
size, 151 bp); for MT-2A, 5’ CCGACTCTAGCCGCCTCTT 3’, and 5’
GTGGAAGTCGCGTTCTTTACA 3’ (product size, 259 bp). The primers for MT-3 were,
upper 5’ CCGTTCACCGCCTCCAG 3’, and lower 5’
CACCAGCCACACTTCACCACA 3’ (product size, 325 bp). The primers for the
determination of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were (upper and
lower, respectively), 5’ TGAAGGTCGGAGTCAACGGATTTGGT 3’ and 5’
CATGTGGGCCATGAGGTCCACCAC 3’ (product size, 983bp. Clonetech Cat No
5406). The primers for the pcDNA3.1hygro(+) vector were
5’CGGATCCACTAGTCCAGTGTG3’ and 5’ACGGGCCCTCTAGACTCG 3’. All MT
primers were obtained from Gibco-BRL. Final concentration of primers for PCR was 0.1
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µM except MT-1X primers. The final concentration of MT-1X primers for PCR was 0.4
µM. After adding 40 µl of master mix into reverse transcribed product, tubes were mixed
gently. All PCR reactions were started with a 95 OC hot start for 2 minutes immediately
prior to cycling. For all PCR reactions the thermocylcer was programmed to cycle at
99 OC for 5 minutes, 68 OC for 30 seconds using GeneAmp PCR System 9700 machine.
Aliquots of 15 µl of PCR products were taken at 25, 30, 35 or 40 PCR cycles
from each reaction tube and combined with 1.5 µl of 10 x gel loading buffer. Controls for
each PCR included a no-template control where water was added instead of the RNA and
a noreverse transcriptase control where water was added instead of the enzyme. For gel
analysis, 2 % agarose (Perkin-Elmer, Cat No 930-2774) was mixed with 0.5x TBE buffer
(Gibco-BRL, Cat No 15546-013) and heated in a microwave until the agarose was
dissolved completely. After cooling at 60 OC, ethidium bromide (0.5 µg/ml) was added to
TBE buffer and poured into a gel mold. Ten µl of RT-PCR product in loading dye was
loaded into each well and 10 µl of Hi-Lo TM DNA marker was used for size marker. The
gels were run at 120 mV for approximately 1-2 hours. The RT-PCR products were
visualized on a UV transilluminator. Digital images of the gels were obtained by
KODAK Professional DCS 420 digital camera interfaced with Adobe Photoshop TM
software, and the intensity of the RT-PCR product bands were quantitated as integral
optical densities (IODs) by Kontron KS 400 image analysis software (Carl Zeiss Vision).
Protein Preparation from cultured cells
The cells were fed with media the day before harvesting proteins. The cells in sixwell plate were rinsed with PBS twice, collected with 500 µl of fresh made cell lysis
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buffer (10 mM Tris-HCl, pH 8.0, 1 mM DTT) and kept at -70 OC until further
investigation. The cell lysates were thawed at 37 OC in a water bath and frozen with
liquid N2. This step was repeated three times. The cell lysates were passed through a 22
gauge needle for several times. After centrifuging for 5 minutes at 12,000xg, the
supernatant was transferred into a new tube. Protein was quantitated by the Bradford
method (BioRad, Ca No 500-0006). The protein was diluted to 1.5 µg/10 µl in cell lysis
buffer and kept at - 70OC until further investigation.
Protein Immuno-dot Blot
An immunoblot procedure was described previously (4, 5). For MT-1 and 2 dot
blot, 0.75 µg of total protein was used. The protein samples were arranged in triplicate in
96-well plates, and each sample well contained 10 µl (0.75 µg) of total protein. For the
MT-1 and MT-2 standards (0, 0.5, 1, 2, 4, 7, 10, and 15 ng MT protein), 1.5 times the
final concentration of MT-1 standard protein (Sigma) was arranged in two rows, with
each standard well contained 0.75 µg of protein extract from the MT null cell line. The
final volume of standard and sample wells was brought up to 75 µl with phosphate buffer.
The 75 µl of 3 % glutaraldehyde was added into the each well and mixed well. Until
loaded on dot blot apparatus, 96-well plates were wrapped with saran brand wrap to
prevent evaporation of samples.
For MT-3 dot blot, 1.5 µg of total protein was applied. For MT-3 standard protein
(0, 0.01, 0.02, 0.04, 0.06, 0.1, 0.2, and 0.3 ng protein), was prepared with 1.5 times
conjugated synthetic peptide (Sigma) and 1.5 µg of BSA protein.
A Sequi-Blot TM PVDF membrane (Bio-Rad, Cat No 162-0182) was soaked in
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methanol for 30 seconds. After washing with dH2O, the membrane was soaked in PBS
until used for the immuno-blot. The dot blot apparatus was assembled and the lower
chamber of apparatus was filled with approximately 50 ml of PBS buffer with a syringe.
The syringe remained attached to the drain tube while the PVDF membrane was carefully
placed over the holes of the plastic adapter without any air bubbles. The top plate was
secured to the lower chamber and the wells were filled with 600 µl of PBS buffer. The
plunger of syringe was pulled out until the wells began draining by gravity. The syringe
was removed and PBS buffer was drained completely. Hundred µl of the samples were
applied to the membrane. After the samples drained completely, 200 µl of PBS was
applied to the membrane twice and then drained completely. The membrane was
removed from the dot blot apparatus, soaked in PBS and kept at 4 OC for overnight.
The membrane was incubated in 50 ml of blocking agent (10 % nonfat milk in
PBS buffer) for 1 hour while shaking a 200 rpm. After washing quickly with 50 ml of
PBS three times, the membrane was incubated three times in PBS buffer for 15 minutes.
The membrane was incubated with 50 ml of primary antibody for 1 hour. The antibody
against MT-1 and MT-2 was E9 antibody (DAKO, Code No M639). This antibody was
diluted to 1:100 with incubation solution (1 % BSA, 0.02 % NaN3 in PBS). The primary
antibody solution against MT-3 solution was composed of 0.187 µg/ ml of primary
antibody with 1 % BSA and 0.02 % NaN3 in PBS buffer. After three times quick washing
with 50 ml of PBS buffer, the membrane was rinsed three times with PBS for 15 minutes.
After incubation with the secondary antibody for 1 hour, the membrane was washed as
above. The secondary antibody for MT-1 and MT-2 was 1:500 dilution of anti33

mouse IgG antibody (Promega, Cat No S372B) with incubation solution (0.4 %BSA,
0.02% NaN3 in PBS buffer). The secondary antibody for MT-3 was 1:500 dilution of
anti-rabbit antibody (Promega, Cat No S3831) with incubation buffer (0.4 %BSA,
0.02 %NaN3 in PBS buffer). The membrane was rinsed with alkaline phosphatase buffer
(10 mM Tris- HCl, pH8.0) for 5 minutes. Colorimetric detection of the alkaline
phosphatase conjugated secondary antibodies was performed by VectorR Blue alkaline
phosphatase substrate kit III (Vector Laboratories, Cat No SK-5300). The solutions 1, 2,
and 3 were added respectively into 25 ml of alkaline phosphatase buffer and mixed gently.
The detection solution was poured on the membrane. The dot blot was developed until
the proper color was visible. After the membrane was washed with water, it was left to air
dry on a piece of paper towel for overnight. After the membrane was scanned as a digital
image, the intensity of dots was measured by KS400 software. The intensity was
quantitated by linear regression in Microsoft Excel.
The antibody against MT-3 protein was generated by immunizing New Zealand
White rabbits with the dodecapeptide GGEAAEAEAEKC (corresponding to MT-3
amino acid, 53-64, which contains the MT-3 unique amino acid insert) conjugated
through the C-terminal cysteine SH group to keyhole limpet hemocyanine using
maleimidobenzoyl-N-hydroxysuccinimde ester. The MT-3 antibody was affinity purified
using the dodecapeptide linked to SulfoLink gel (Pierce, Rockford, IL) through the Cterminal cysteine residue.
Chronic exposure to arsenic or cadmium of UROtsa cells
NaAsO2 was prepared as a 1 mM stock solution with water and added to cell
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culture medium before feeding cells. The passage numbers of UROtsa cells in serum and
serum-free medium were 88 and 51, respectively. Cells were fed with 1 µM arsenic
containing fresh medium once every three days. Two months later cells were fed every
other day with extra glucose because cells would die due to cellular toxicity resulting
from acidic pH of the medium. Approximately three months after exposure to arsenic,
cells began growing fast. Therefore, the cells were subcultured 1:10 ratio after three
months exposure. The untreated UROtsa cells were usually subcultured 1:4 ratio and
reached 100% of confluence in 7-8 days after subculturing. These chronically arsenic
exposed UROtsa cells were subcultured 1:10 ratio and reached 100 % of confluence in 56 days after subculturing.
UROtsa cells were cultured on 6 well plates both with regular and serum free
media. Upon reaching 90 % confluence, 1 µM CdCl2 was added into each well. After
cells reached confluence, cells were subcultured at 1:4 ratio in T75 flasks. Transfer
resulted in 90 % cell death followed by regrowth of the cells. The cells were fed with
fresh media containing metals once every three days. One month later, after the cells
were transferred into the T75 flask, extra glucose (1 mg/ml) was added to cell culture
medium and two months later, cells were split 1:10 ratio. The RNA and protein samples
were collected every four serial subcultures.
Growth rate of transformed UROtsa cells
Cells were cultured in T75 flask with or without 1 µM CdCl2 or 1 µM NaAsO2.
After being trypsinized and resuspended, cells were seeded to a 1:20 ratio in six-well
plates with or without metals. The exposed UROtsa cells were used as a control. For
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rescued condition, exposed cells were cultured without arsenic or cadmium for two
weeks. Then cells were seeded to 1:20 ratio in 6 well-plates and maintained without
arsenic or cadmium and monitoered the growth rate by recording absorbance at 570 nm
every 24 hours for 6 days by MTT assay. The growth rate, expressed as doubling time,
was calculated from the slope of linear regressed plots of LN (cell number) vs. time (6).
The absorbance at 570 nm was measured instead of cell numbers in this study; slope was
calculated after absorbance value was multiplied by 100 and integrated. The integrated
value was used for regression and the x value was used for slope.
Soft Agar Assay
Soft agar assays were performed using standard procedures (7). 1.01 % of noble
agar in DMEM was heated until dissolved on the hot plate. After mixing with the same
volume of 1.01 % noble agar and cell culture media, 5 ml mixture (0.55 % agar) was
poured in 60 mm plates and solidified at room temperature. The remaining mixtures were
kept at45 OC water bath to prevent solidification. After trypisinization, cells were
resuspended in culture media and counted. 2x 105 cells in medium were mixed with half
volume of 0.55 % noble agar containing medium. 1.5 ml of 2x105 cells in 1.5 ml of
0.275 % noble agar containing medium was poured onto the 5 ml of bottom layer of
0.55% noble agar containing medium in 60 mm dish. The 60 mm dishes were put inside
the box which has two water contained beakers. This moisturized box prevented
dehydration of soft agar in 60 mm dishes. Then this box was put back to the cell culture
incubator. The next day cells were observed under microscope to make sure all cells were
single. One week later, cells were observed under the microscope to see how many cells
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formed colonies. Three weeks later, colonies containing more than 10c ells were
photographed and counted.
Nude Mice and Transformed Cell Injection
A nude mouse tumorigenicity assay was performed (8). Athymic nude mice (NCr
nu/nu) were obtained through the National Cancer Institute. All animal care procedures
were in strict accordance with state of the art animal resource facility (20,600 GSF 1,
7950 NSF). All animals were fed with LabDiet5001 (TestDiet). Four different
transformed cell types were injected into nude mice: 1 µM cadmium exposed UROtsa
cells in serum medium, 1 µM cadmium exposed UROtsa in serum-free medium, 1 µM
arsenic exposed UROtsa in serum medium, and 1 µM arsenic exposed UROtsa in
serumfree medium. Transformed cells were cultured in T75 flasks. The cells were
trysinized and centrifuged briefly. The cells were resuspended with 1 ml of PBS buffer.
The resuspended cells were inoculated subcutaneously in the dorsal thoracic midline of
11 approximately eight-week-old female nude mice for each transformed cell lines. All
mice were sacrificed 5-9 weeks after injection. Each tumor sample was divided into three
pieces for histology, RT-PCR and protein dot blot. For histology, tumor tissue was kept
in 10 % formalin after removal from mouse. For RT-PCR and protein dot blot, tumor
tissue was kept in liquid N2 before transferring to – 70 OC for further investigation. PC-3,
the prostate cancer cell line, was used as a control for this experiment.
Hematoxylin and Eosin Staining
The tumor was removed from the nude mouse and cut out as a small piece of
tissue (usually 10 mm x 10 mm x 3mm) and fixed overnight in 10 % neutral formalin.
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The tissues were incubated in two washes of 10 % formalin for one minute each, 70%
alcohol for one minute, 95 % alcohol for one minute and fourth washes of 100 % alcohol
for one minute four times. Dehydrated tissues were cleared in xylene, infiltrated and
embedded in paraffin, and sectioned with a sharp knife at 5 µm thick as serial sections.
The serial sections were put on covered slide and dried. The slides were kept at room
temperature until further investigation. The slides were deparaffinzed by three times
incubation of clean xylene for three mintues, followed by two washes from absolute
ethanol to 95, 80, and 70 % ethanol, and washed in distilled water for two minutes. The
slides were incubated with hematoxylin for seven minutes, dipped 10 times in tap water,
dipped 3-5 times in acidic alcohol (3 % HCl in 70 % ethanol), and washed in tap water.
Tissue was dipped 3-5 times in lithium carbonate, washed in tap water and stained in
eosin for 45 seconds. The tissue was dehydrated by washed in 95 and 100 % alcohol
twice. Finally, tissue was incubated with xylene twice for three minutes and covered with
cover slip and dried at room temperature.
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Introduction
Recent studies demonstrate that MT-3 is up-regulated in human bladder cancer
and might serve as a biomarker for bladder cancer because it is not expressed in normal
urothelium but is overexpressed in most bladder cancers, with expression correlating
directly to increasing tumor grade (1, 2). Immunohistochemical analysis showed that
MT-3 staining was intense in both carcinoma in situ and high-grade bladder cancer, and
low to moderate in low-grade cancers and dysplastic lesions. This was based on
determining the localization and expression of the MT-3 protein and mRNA in fresh and
archival biopsy specimens from patients undergoing differential diagnosis for a variety of
bladder disorders. While these observations suggest an important role for MT-3 in human
bladder cancer, there are only limited data in humans and animals for development of a
hypothesis to explain the up-regulation of MT-3 gene expression.
The UROtsa cell line was derived from the normal urothelium lining the ureter of
a 12-year-old girl and was immortalized by SV40 large T-antigen (3). The cells did not
acquire characteristics of neoplastic transformation as noted by lack of colony formation
in the soft agar and growth of tumors in nude mice (3). The previous study showed that
propagation of the UROtsa cell line on serum-free growth medium results in expression
of structural features of differentiated urothelium (4). Ultrastructure analysis has shown
detailed organization of these multilayered mounds and freeze-fracture has revealed the
presence of specialized intercellular junctions including zonula occluden. These findings
are significant in that UROtsa appears to have similar characteristics of in vivo human
urothelium. Previous studies also showed that the UROtsa cell line didn’t express MT
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isoform 3 and thus this cell line was suggested as a useful model system for determining
functional consequence of forcing MT-3 overexpression on the normal urothelial cell (4).
Objectives of the Study
The first goal of this study was to see the effect of MT-3 overexpression in the
normal human bladder epithelial cell line. The second goal was to develop the UROtsa
cell system as a model for the overexpression of MT-3 in bladder cancer and the MT
stress response of normal urothelium.
Results
The UROtsa cell line was stably transfected with MT-3 gene under control of the
cytomegalovirus (CMV) promoter, or the blank vector without the MT-3 gene. The
stable transfectants were selected by 30 µg/ml hygromycin B. The selected clones were
cultured in serum-free medium for further investigation. As confirmed in the previous
study, MT-3 mRNA was not detected in the blank vector transfectants and parental
UROtsa cells by 40 cycles of PCR at an input of 500 ng total RNA (Fig 1A). Immuno-dot
blot analysis of the corresponding protein sample from these wild type UROtsa cells
demonstrated no detectable MT-3 protein (data not shown). Four MT-3 transfected clones
were selected for the further investigation. MT-3 mRNA was detected at 25 cycles of
PCR and 500 ng of total RNA inputs (Fig 1A). RT-PCR of glyceraldehydes 3-phospate
dehydrogenase (gapdh) in all these cells was performed as a control of input of amount of
total RNA (Fig 1B). In contrast to the high levels of MT-3 mRNA expression, the MT-3
protein was not detected in these MT-3 transfected clones (data not shown). To confirm
this data, sixteen more clones were selected and analyzed by RT-PCR and immuno-dot
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Fig. 1. Stable overexpression of MT-3 mRNA in UROtsa cells. Total RNA was
isolated from nontransfected cells and clones of MT-3 or control vector-transfected cells
and RT-PCR was performed. (A) MT-3 mRNA was detected from each of the four MT-3
transfected clones at 25 cycles of PCR with MT-3 specific primers. MT-3 mRNA was not
detected from nontransfected and control vector-transfected clones at 40 cycles with MT3 specific primers. (B) RT-PCR for the housekeeping gene, glyceraldehydes 3-phosphate
dehydrogenase (gapdh), performed at 30 cycles with gapdh specific primers. The total
RNA was used from the same RNA in (A).
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blot for MT-3 protein. All selected clones of MT-3 transfected UROtsa cells showed the
expression of MT-3 mRNA (Fig 2A). All sixteen MT-3 transfected clones did not express
noticeable levels of MT-3 protein (Fig 2B). To confirm that the MT-3 gene inserted into
pcDNA3.1/Hygro (+) plasmid construct was functional, the plasmid construct was
transfected into PC-3 (prostate cancer), HS578T (breast cancer), HK-2 (kidney), and
MCF-7 (breast cancer) cell lines. RT-PCR data confirmed the successful isolation of MT3 transfected clones from each cell line. The immuno-dot blot data also showed
successful expression of MT-3 protein from the alternative cell lines (Fig 2B). These
results demonstrate that the low accumulation of MT-3 protein in transfected UROtsa
clones was neither because of MT-3 plasmid misconstruction nor problems with the MT3 immuno-dot blot detection system. The UROtsa cells containing the MT-3 vector were
named UROtsa(MT3) cells and those containing the unmodified vector named
UROtsa(3.1).
There are several indications that induction of MT protein synthesis is blocked by
RNA synthesis inhibitors even though mRNA level is increased (5). The half-lives of MT
are tremendously different when bound to various heavy metals (6). These studies
suggest that MT accumulation is also regulated by post-transcriptional processes or
protein stabilities. This hypothesis also is supported by previous studies that exposure of
cells to cadmium and copper can increase the level of the MT-1 and MT-2 at the
posttranscriptional level by stabilizing the protein against degradation (7, 8,9). Even
though MT-3 protein is synthesized in UROtsa(MT3) cells, protein may be degraded
rapidly due to lack of metals to bind. To test this hypothesis, UROtsa(MT3) and
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Fig. 2. Expression of MT-3 in 16 MT-3 gene transfected UROtsa clones compared to
other MT-3 gene transfected cell lines. (A) The mRNA expression assessed by RTPCR
and reported as relative IOD (IOD of the MT-3 RT-PCR product band at 30 cycles
normalized to that of GAPDH at 30cycles). (B) MT-3 protein expression was measured
by immuno-dot blot. PC-3 is prostate cancer cell line , HK-2 is kidney cell line, and
HS578T and MCF-7 are breast cancer cell lines. Triplicate RT-PCR and immuno-dot blot
were analyzed and shown are the mean and standard error.
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UROtsa(3.1) cells were exposed to metals and MT-3 protein was measured. The cells
were cultured with 1, 5 and 9 µM concentration of cadmium in serum-free medium up to
16 days. Cell viability was determined by the MTT assay. MTT assay data showed no
cellular toxicity with 1 µM CdCl2, intermediate level of cell death with 4 µM CdCl2 and
a high level of cell death with 9 µM CdCl2 in both UROtsa(MT3) and UROtsa(3.1) cells
(Fig 3A.,3B). There was no difference in sensitivity to cadmium between UROtsa(MT3)
and UROtsa(3.1) cells. The total RNA and proteins were collected from these cadmium
exposed cells for RTPCR and immuno-dot blot. Previous study showed that MT-1E, MT1X and MT-2A were expressed in UROtsa cell line (4). As expected, mRNAs of MT-1E,
MT-1X and MT-2A were induced by cadmium in both cell types (Fig 4, Fig 5). Exposure
of UROtsa(MT3) cells to cadmium had no effect on the expression of the MT-3 protein
compared to UROtsa(3.1) cells at any point in the time course up to 96 hrs (Fig. 6). In
contrast, an identical exposure to cadmium produced significant increases in the MT-1
and MT-2 protein at all concentrations of cadmium both UROtsa(MT3) and UROtsa(3.1)
cells (Fig. 7).
Zinc is an essential metal during cell proliferation and differentiation (10).
Intracellular levels of zinc are critical for induction of the MT genes since metal response
element transcription factor -1 (MTF1) is a zinc-finger transcription factor and is well
known as trans-acting element for MT gene expression (11, 12). Several studies have
shown that zinc containing MT shows more resistance to protease than cadmium
containing MT and cadmium and zinc may regulate MT in differently (13). To test
whether or not zinc may stabilize MT-3 protein, UROtsa(MT3) and UROtsa(3.1) cells
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Fig. 3. Viability of UROtsa(3.1) and UROtsa(MT3) cells exposed to cadmium
chloride. Cell viability was determined by MTT assay and all determinations were made
in triplicate. The graphed values are expressed as percentages of mean absorbance of
treated cells divided by the mean absorbance of control cells for each triplicate
determination. (A)Viability profiles of UROtsa(3.1) (B) UROtsa(MT3). Triplicate of
immuno-dot blot were analyzed and shown are the mean and standard error.
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Fig. 4. Expression of metallothionein isoforms in UROtsa(3.1) cells exposed to
cadmium chloride The cells were exposed to three levels of cadmium for up to 96 hours
and harvested at the indicated time points. (A) Expression of MT-1E mRNA at 33 cycles.
(B) Expression of MT-1X mRNA at 28 cycles (C) Expression of MT-2A mRNA at 28
cycles. The IOD of the MT RT-PCR product normalized to that of GAPDH (25 cycles)
and divided by control IOD. Triplicate culture samples were analyzed and shown are the
mean and standard error.
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Fig. 5. Expression of metallothionein isoforms in UROtsa(MT3) cells exposed to
cadmium chloride. The cells were exposed to three levels of cadmium for up to 96
hours and harvested at the indicated time points. (A) Expression of MT-1E mRNA at 33
cycles. (B) Expression of MT-1X mRNA at 28 cycles (C) Expression of MT-2A mRNA
at 28 cycles. The IOD of the MT RT-PCR product normalized to that of GAPDH (25
cycles) and divided by control IOD. Triplicate culture samples were analyzed and shown
are the mean and standard error.
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Fig. 6. Expression of metallothionein-3 in UROtsa(MT3) cells exposed to cadmium
chloride. The cells were exposed to three levels of cadmium for up to 96h and harvested
at the indicated time points. Levels of MT-3 protein were determined using an
immunodot- blot with an MT-3 specific antibody. Shown are the means and SE of
triplicate cell samples.
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Fig. 7. Expression of metallothionein-1/2 protein in UROtsa(3.1) (A) and
UROtsa(MT3) (B) cells exposed to cadmium chloride. Nanograms of MT-1/2 protein
expressed at various time points in UROtsa cells exposed to three levels of cadmium up
to 96h and harvested at the indicated time points . Levels of MT-1 and 2 proteins were
determined using an immuno-dot blot with an E9 antibody. Shown are the means and SE
of triplicate cell samples.
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were exposed to zinc chloride for up to 72 hours. MTT assay showed that 50 and 100 uM
zinc were not lethal (Fig. 8). MT-3 protein did not accumulate (Figs.9, 10). In contrast,
MT-1 and MT-2 proteins were induced by zinc up to four folds.
The conclusion drawn from studies with UROtsa(MT3) cells is that transfected
MT-3 gene is successfully transcribed but not translated very efficiently. As discussed
earlier, MT-3 is different from other metallothionein isoforms in many ways. Therefore,
it was of interest to determine whether or not other MT isoforms are translated in UROtsa
cell line. The MT-1E is one of the common and well studied isoforms. To confirm that
MT-1E had been successfully transfected into UROtsa cells, pcDNA3.1/Hygro (+)
specific primer was used for RT-PCR because the UROtsa cells showed basic level of
MT-1E mRNA. RT-PCR for 30 cycle data showed that MT1E was successfully
transfected and transcribed (Fig. 11). The MT-1E transfected UROtsa cells were named
UROtsa(MT1E). The UROtsa(MT1E) cells were exposed to 1, 5, and 9 µM CdCl2 up to
96 hours. The MTT assay showed no toxic effect of cadmium at any time course (Fig. 12).
The MT-1 and MT-2 proteins in UROtsa(MT1E) were increased more than 60 %
compared to the basal levels in UROtsa(3.1) (Fig. 7A, Fig. 13). This result demonstrated
that the inserted MT-1E gene was transcribed and translated in the UROtsa cell line.
Discussion
The initial goal of this study was to investigate that the consequences of the stable
transfection of MT-3 gene into immortalized human urothelial cell line. The stable
transfection of MT-3 resulted in the expected overexpression of MT-3 mRNA but the
level of MT-3 protein was similar to that of the background levels found in the parental
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Fig. 8. Viability of UROtsa(3.1) (A) and UROtsa(MT3) (B) cells exposed to zinc.
Cell viability was determined by MTT assay and all determinations were in triplicate.
The graphed values are expressed as percentages of the mean absorbance of treated cells
Divided by the mean absorbance of control cells for each triplicate determination.
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Fig. 9. Expression of metallothionein-1/2 protein in UROtsa(3.1) (A) and
UROtsa(MT3) (B) cells exposed to zinc. Nanograms of MT-1/2 protein expressed at
various time points in UROtsa cells exposed to three levels of cadmium up to 72h and
harvested at the indicated time points . Levels of MT-1 and 2 proteins were determined
by an immuno-dot blot with an E9 antibody. Shown are the means and SE of triplicate
cell samples.
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Fig. 10. Expression of metallothionein-3 in UROtsa(3.1) (A) and UROtsa(MT3) (B)
cells exposed to zinc. Cells were exposed to three levels of zinc chloride for up to 72h
and harvested at the indicated time points. Levels of MT-3 protein were determined using
an immuno-dot blot with an MT-3 specific antibody. Shown are the means of triplicate
cell samples.
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Fig 11. Stable overexpression of MT-1E mRNA in UROtsa cells. Total RNA was
isolated from nontransfected cells and clones of MT-1E or control vector-transfected
cells and RT-PCR was performed. PCR was performed by using pcDNA3.1 especific
vector. MT-1E mRNA was detected from MT-1E transfected clones at 30 cycles of PCR.
MT-3 mRNA was not detected from nontransfected and control vector-transfected clones
at 30 cycles.
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Fig 12. Viability of UROtsa(MT1E) cells exposed to cadmium chloride. The cell
viability of MT-1E transfected UROtsa cells was determined by MTT assay. The
absorbance at 570 nm for each of the three treatments, as well as untreated cells were
measured in triplicate at hours 6, 12, 24, 36, 48, 72 and 96. Each of the treatments (1, 5
and 9 µÌ cadmium chloride) was plotted as separate lines expressed as a percentage of
mean absorbance of treatments divided by mean absorbance of untreated controls for
each triplicate determination. Shown are the means and standard error of triplicate cell
samples.
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Fig 13. Effect of cadmium on MT-1/2 protein expression in UROtsa(MT1E) cells.
The MT-1E transfected UROtsa cells were exposed 1, 5, and 9 µM cadmium and cell
lysates were prepared at 0, 6, 12, 24, 36, 48, 72 and 96 hours for determination of MT-1/2
protein levels.
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cells and blank vector control. This finding was unexpected since other studies using the
identical vector and transfection protocol did result in the overexpression of both MT-3
mRNA and protein. Recent rodent studies demonstrated that there was no clear
relationship between MT-1 and MT-2 mRNA and protein levels (8). In adult mouse
injected with copper or cadmium, MT protein levels in liver did not change even though
mRNA expression increased. In contrast, MT protein levels in kidney increased with
increased mRNA levels. It is well-documented for MT-1 and MT-2 isoforms that in
addition to transcriptional control, there is also a component of post-transcriptional
control that depends on the metal saturation state of the MT-1 and MT-2 proteins (14, 15).
MT protein is susceptible to degradation when devoid of metal, and stabilizes against
degradation upon metal binding and saturation of the binding sites. These studies suggest
that the failure of the stably transfected UROtsa cells to accumulate MT-3 protein in the
presence of elevated MT-3 mRNA might operate through a similar mechanism involving
metal saturation and stability of the MT-3 protein. This hypothesis was tested in the
present study and there was no effect on MT-3 protein accumulation when MT-3
transfected UROtsa cells were exposed to cadmium. This finding demonstrates that metal
saturation of MT-3 protein is not a potential mechanism to explain the posttranscriptional
restriction of MT-3 protein accumulation in the transfected UROtsa cells.
In contrast, the MT-1 and MT-2 proteins were accumulated to higher levels under
identical conditions of cadmium exposure in the MT-1E transfected UROtsa cells.
Several cell lines transfected with MT-1E did not show any difference from parental or
blank vector transfected cells. These findings are the first indication that some cell types
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possess a specific mechanism for the post-transcriptional regulation of MT-3 protein
expression.
Although the exact mechanism of post-transcriptional regulation of MT-3 protein
is still unknown, there is evidence that its activity in cell culture may be defined by the
tissue of origin. The stable transfection of MT-3 gene in several cancer cell lines such as
PC-3 (prostate caner), MCF-7 (breast cancer) and Hs578T (breast cancer) resulted in
decreased cell growth rate due to overexpression of MT-3 protein (16, 17). The primary
human proximal tubule (HPT) cells expressed MT-3 mRNA and protein by stable
transfection and accumulated increased protein upon exposure to cadmium. The
immortalized HK-2, proximal epithelial cells, showed increased MT-3 protein upon
exposure to cadmium in MT-3 transfected clones and formed domes that may involve
vectoral active transport (18). The MCF-10 (immortalized breast cell line) failed to make
MT-3 protein after stable transfection (publication under preparation). These studies
suggest that regulation of MT-3 expression may involve specific function of MT-3
proteins in different cell types.
In conclusion, MT-1E and MT-3 genes were stably trasnfected into the UROtsa
cells. The transfected MT-1E gene was efficiently translated in the UROtsa cells but was
not MT-3 gene. Even though the transfected MT-3 gene was transcribed in the UROtsa
cells, the MT-3 gene appears to be regulated at the post-transcriptional level in the
UROtsa cells. This study indicates that the regulation of MT-3 expression is different
from other MT isoforms.
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In vitro Transformation of UROtsa Cell Line by Chronic Exposure to
Arsenic or Cadmium
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Introduction
Human exposure to hazardous chemicals is common due to their wide usage in
industry and their persistence in the environment. Cadmium is an important industrial and
environmental pollutant and is classified as a carcinogen by the International Agency for
Research on Cancer and the US National Toxicology Program based on an association
between occupational or environmental cadmium exposure and development of cancers
of the lung, prostate, kidney, liver, stomach and bladder (1). Even though the
epidemiological studies suggest a link between cadmium exposure and various human
cancers, mechanisms of cadmium-induced carcinogenesis are still unclear (1). Since
cadmium is not considered a mutagen, several indirect genotoxic carcinogenic
mechanisms have been suggested for the altered gene expression and disruption of
cellcell adhesion. Several studies demonstrated that cadmium may replace Ca2+ in cellcell adhesion, resulting in disruption of cell-cell adhesion and changes of gap junctional
communication (2-4). Chronic exposure to cadmium caused overexpression of cellular
proto-oncogenes including c-fos, c-jun and c-myc and resulted in change of cellular
proliferation and modification of signal transduction pathway (5). The environmental
contaminant arsenic is considered as a human carcinogen. Arsenic occurs naturally in
drinking water with levels ranging up to thousands of ppb. It is reported that ingestion of
arsenic leads to skin lesions and an elevated risk of skin cancer (6). The arsenic ingestion
through drinking water is associated with an elevated number of micronuclei in epithelial
bladder cells in exposed populations (7). This indicates cytogenetic damage to bladder
cells and strengthens the evidence that arsenic may cause bladder cancer and other
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internal cancers. The epidemiological observation supports that arsenic is also associated
with various cancers in humans, including tumors of the lung, skin, bladder and liver (8).
Several studies demonstrated that low-level of chronic exposure to arsenic causes
malignant transformation of epithelial cells by global DNA hypomethylation and aberrant
gene expression (9-11). Interestingly, arsenic has also been used as an effective
chemotherapeutic agent in the treatment of certain human cancers especially in leukemia
(12). The chronic exposure to low concentrations of arsenic induces cell transformation,
whereas higher concentrations of arsenic induce cell apoptosis (13, 14).
Several cell culture systems have been developed to investigate the carcinogenic
mechanism of environmental chemicals in various cancers (15). The bladder cancer is an
environmentally induced cancer and this cancer is clearly linked with environmental
chemicals and smoking. Since the major risk factor for bladder cancer is occupational and
environmental exposure to chemicals, it is important to establish in vitro transformation
model comprised of human urothelial cells, the common target cells for the these
environmental contaminants (16, 17). Several reports have demonstrated the successful
transformation of human uroepithelial cell lines by chronic exposure to various potential
carcinogens but none have demonstrated the development of arsenic or cadmium-induced
in vitro transformation model system in human urothelial cell line (18, 19).
The UROtsa cell line was isolated from a primary culture of normal human
urothelium through immortalization with a construct containing the SV40 large T antigen
(20). It proliferates in serum-containing growth medium as a cell monolayer with little
evidence of uroepithelial differentiation. When these cells are cultured in serum-free cell
66

culture medium, they are differentiated and express known features that strongly
resemble in situ urothelium (21). These findings suggest that the UROtsa cells grown
with serum-free medium could be a valuable tool for studying environmental insult to the
human urothelium in general and in particular the stress response to environmental
pollutants. The first aim of this study was to determine whether or not chronic exposure
to low concentration of arsenic or cadmium results in in vitro transformation of human
urothelial cell line. The second aim of this study was to develop an in vitro
transformation model system for arsenic or cadmium induced transformation in human
urothelial cells.
Results
In this study, chronic exposure to arsenic or cadmium showed no significant
morphological difference of UROtsa cells compared with unexposed UROtsa control
cells (Fig. 14). The cellular morphology is another good indicator for proliferative ability
of cells. Highly dividing cells show a characteristic small and morphologically
homogeneous cell type. By contrast, slowly dividing or senescent cells are larger with a
high incidence of morphological heterogeneity (22). The larger and morphological
heterogeneous cells appeared at the earlier stages of exposure to the two chemicals. These
cells were not common at later stages of exposure.
To determine the change in the rate of growth in UROtsa cells following chronic
exposure to arsenic or cadmium, growth rates were determined by MTT assay for 1 µM
cadmium treated UROtsa cells in serum medium and serum-free medium for seven
months, 1 µM arsenic treated UROtsa cells in serum medium and serum-free medium for
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Fig. 14 Phase contrast photomicrographs of human urothelial cell line.
Picture (A) and (B) represent the control UROtsa cells. (A) The UROtsa cells were
cultured in cell culture medium contained 5 % fetal bovine serum. Cells showed 100 %
confluence. (B) UROtsa cells were cultured in serum-free medium. Cells started to form
three-dimensional structure.
All exposed cells were cultured with arsenic or cadmium for 9-10 weeks. (C) UROtsa
cells with 1 µM arsenic were cultured with serum medium. Cells were 95 % of
confluence and showed a characteristic epithelial morphology with phase-bright in
intercellular borders and numerous mitotic figures. (D) UROtsa cells with 1 µM arsenic
were cultured without serum. (E) UROtsa cells with 1µM cadmium were cultured with
serum medium. Cells were above 100 % of confluence. (F) UROtsa cells with 1 µM
cadmium were cultured without serum. All exposed cells showed no significantly
different morphology. Magnification: 10 x
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seven months, and untreated wild type UROtsa cells in serum medium as a control (Fig.
15). The results demonstrated that chronic exposure to arsenic or cadmium in serum
medium had an increased growth rate compared with untreated cells (Table 1A). The
mean doubling time of the arsenic treated UROtsa cells in serum medium was 22.04
hours compared with a doubling time of 43.13 hours in untreated UROtsa cells in serum
medium. In contrast, the growth rate of arsenic or cadmium exposed UROtsa cells in
serum-free medium did not show significantly difference from untreated cells. The
growth rates of UROtsa cells in serum medium are greater than those of UROtsa cells in
serum-free medium. There was no significant difference of growth rate between arsenic
and cadmium exposed cells. Even though the growth rates of arsenic or cadmium
exposed UROtsa cells with serum were changed, there was no morphological difference.
To demonstrate whether or not arsenic or cadmium in medium involved increased growth
rates in these exposed cells, the exposed cells were cultured without arsenic or cadmium
for two weeks. Then these cells were subcultured at a 1:20 ratio and fed once every other
day without arsenic or cadmium continuously. The results demonstrated that rescued
cells showed no significant difference on the growth rate of the cells when compared with
non-rescued cells (Table 1B). This result demonstrated that the growth rate of chronic
exposure to arsenic or cadmium UROtsa cells in serum medium was not due to the
presence of arsenic or cadmium in medium. It suggests that chronic exposure to arsenic
or cadmium results in increased growth rate of UROtsa cells and this change is not
reversible by removal of arsenic or cadmium from medium. Similar result was reported
when in vitro transformed rat liver cells by arsenic were cultured without arsenic for six
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Fig. 15 The effect of cadmium or arsenic exposure on UROtsa cell growth .
Determination of growth rates of untreated UROtsa cells, UROtsa cells with 1 µM CdCl
or 1 µM NaAsO2 exposed for seven months both in serum medium or serum-free
medium was performed by seeding cells at a 1:20 ratio and recording absorbance at 570
nm at the indicated time point by MTT assay. The results presented are an average of
duplicate determinations of MTT assay per plate ± S.E.
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Table 1. Effect of exposure to arsenic or cadmium on doubling time of UROtsa cells.
The three months exposed UROtsa cells were used in this experiment. The growth rate,
expressed as doubling time, was calculated from the slope of linear regressed plots of LN
(cell number) vs. time. By using absorbance value at 570 nm in Fig. 2, slope was
calculated by multiplying with 100 and integrated. The integrated value was used for
regression and the x valuable was used for slope. Table (A) represents growth rates of
continuously exposed UROtsa cells. (B) After exposing for seven months, cells were
rescued from arsenic or cadmium for two weeks. During growth rate measurement for
one week, cells were not exposed to arsenic or cadmium.
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weeks and inoculated in the nude mice. Cells formed aggressive tumors in nude mice
(10).
To test whether or not arsenic or cadmium exposure induces anchorage
independent colony formation, soft agar assay was performed. Figure 16 shows the
results of a typical experiment demonstrating colony formation in soft agar by UROtsa
cells exposed to arsenic or cadmium. All of the unexposed UROtsa cells failed to grow in
soft agar, whereas seven-month exposed cells exhibited the capacity to form colonies in
soft agar (Fig. 16). To demonstrate that there was no methodological error of soft agar
assay, PC-3 cells were used as positive control for all soft agar assays since several
studies demonstrated colony formation of PC-3 cells in soft agar (23). The exposed
UROtsa cells in serum medium formed bigger and more colonies than those in serumfree
medium. The colonies were counted at a magnification of 10 x after three weeks in
soft agar (Fig. 17). The UROtsa cells in serum medium containing 1 µM arsenic formed
18 +/- 2.57 colonies per field, whereas cells in serum-free medium containing1 µM
arsenic formed 3.17 +/- 0.67 colonies per field. The UROtsa cells in serum medium with
1 µM cadmium formed 10.83 +/- 1.96 per field and cells in serum-free medium with 1
µM cadmium formed 0.58 +/- 0.16 colonies per field. The total colony number of
UROtsa cells with cadmium in serum-free was 315 +/- 45 colonies per 2x105 cells. The
data demonstrate that UROtsa cells in serum medium formed more colonies than in
serum-free medium.
The soft agar assay assesses the ability of cells to grow in the absence of adhesion,
one of the in vitro characteristics of transformation (24). The ability of arsenic or
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Fig. 16 Effects of arsenic or cadmium exposure to UROtsa cells in colony formation
Assay. A total of 2 x 105 cells were plated in duplicate in 1.5 ml of 0.275 % agar in cell
culture medium onto the 5ml of bottom layer of 0.5 % agar in 6-cm dish. The dishes were
incubated at 37OC in a humidified 5 % CO2 incubator. Colonies were counted and
photographed three weeks after plating. For control, PC-3 cells (A) and untreated UROtsa
cells (B) were used. All treated UROtsa cells were exposed to arsenic or cadmium for
seven months: (C) 1 µM arsenic exposed with serum, (D) 1 µM arsenic exposed without
serum, (E) 1 µM cadmium exposed with serum, (F) 1 µM cadmium exposed without
serum. Magnification: 10 x.
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Fig. 17 Colony-formation capacity of UROtsa cells. The UROtsa cells were exposed to
1 µM arsenic or 1 µM cadmium for seven months. 2x105 cells per dish were incubated
with 0.275 % agar for three weeks at 37OC in 5 % CO2. The colonies of >10 cells were
counted at 10 x of magnification for 6 fields per dish. The sAs and sCd represent UROtsa
cells in arsenic and cadmium in serum medium, respectively. The fAs and fCd represent
UROtsa cells in arsenic and cadmium in serum-free medium. The results presented are an
average of duplicate determinations of visible colonies per plate ± S.E.
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cadmium exposed UROtsa cells to form colonies in soft agar suggests that they were
fully transformed and may have a possibility to form tumors in nude mice.
To test the expression of metallothioneins during chronic exposure to arsenic or
cadmium in UROtsa cells, levels of protein from arsenic or cadmium-seven months
exposed cells were measured by immuno-dot blot. Levels of metallothionein-1 and 2
proteins increased dramatically compared to unexposed cells, 1.56 +/- 0.01 ng/µg of total
protein (Fig. 18A). The MT-1 and 2 proteins in cadmium exposed UROtsa cells with or
without serum showed 17.65 +/- 0.4 ng/µg and 16.23 +/- 0.95 ng/µg, respectively. The
MT-1 and 2 proteins in arsenic exposed UROtsa cells with or without serum showed 2.9
+/- 0.36 ng/µg and 9.38 +/- 0.47 ng/µg, respectively. There was no significant difference
in induction levels of MT-1 and MT-2 with or without serum in cell culture medium. The
levels of metallothionein-3 protein in all exposed UROtsa cells were between 0.13 and
0.24 ng/µg (Fig. 18B). These levels were considered as undetectable levels of protein due
to nonsepecific binding of immuno-dot blot systems.
Discussion
The transformation of normal cells into cancer cells requires series of distinct
steps involving uncontrolled cellular proliferation, loss of intercellular adhesion, and gain
of angiogenesis. Evidence indicates that tumorigenesis is a multistep process and these
steps are consequences of genetic alterations that evolve progressively from normal via
series of premalignant states into invasive cancers (25). Many of these phenomena have
linked the extracellular matrix (ECM) to the development and control of malignancy.
Cellular interactions with the ECM control cell adhesion, motility, and cellular matrix
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Fig. 18 Expression of metallothionein protein in UROtsa cells. The UROtas cells with
1 µM arsenic or 1 µM cadmium exposed for seven months and total protein was collected.
Total 0.75 µg and 1.5 µg of protein was used for immuno-dot blot of metallothionein-1/2
and metallothionein-3, respectively. Panel (A) represents of metallothionein-1 and
metallothionein-2 protein and panel (B) represents of metallothionein-3 protein. The sAs
and sCd represent UROtsa cells in arsenic and cadmium in serum medium, respectively.
The fAs and fCd represent UROtsa cells in arsenic and cadmium in serum-free medium.
Levels of MT-1 and 2 proteins were determined using an immuno-dot blot with an E9
antibody. Level of MT-3 protein was determined using MT-3 specific antibody. Shown
are the means and SE of triplicate cell samples.
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degradation involve malignant phenotype. The characteristics of neoplastic cells, which
distinguish from their normal counterparts, may be important to understand the
mechanisms of malignant transformation. Therefore, in vitro transformation model
systems are very useful tools in the understanding of fundamental differences between
normal cells and tumors cells if both have been derived from a common source. Although
many studies have reported tumorigenesis by exposure to arsenic or cadmium, the
mechanisms of arsenic- or cadmium- induced carcinogenesis are still unclear.
In this study, we showed that chronic exposure to arsenic or cadmium resulted in
in vitro transformation of human uroepithelial cell line based on anchorage-independent
growth. Appropriate observation on characteristic changes of UROtsa cells with arsenic
or cadmium may reveal multiple steps of tumorigenesis in bladder cancer.
The first change of in vitro transformation of UROtsa cells was increased
metabolic rates compared with those of unexposed cells. After exposure to arsenic or
cadmium for up to 8 weeks, UROtsa cells required extra glucose for survival. The
cellular metabolic rate is controlled by a number of processes including metabolic
demand and substrate supply. The next two differences were increased growth rate and
anchorage-independent growth. After three months exposure to arsenic or cadmium,
cellular proliferation rate had increased. When growth rates of seven-month exposed cells
were measured, growth rate of exposed cells with serum was twice as high as that of
control cells. After exposure to arsenic or cadmium for seven months, UROtsa cells with
serum formed colonies in soft agar. The growth rate of transformed UROtsa cells without
serum was not changed even though these cells formed colonies in soft agar. This result
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suggests that increased growth rate may be followed by anchorage-independent growth.
The most interesting result is that there was a significant difference in the in vitro
transformation of UROtsa cells depending on which cell culture system was used. There
are several possibilities to explain this phenomenon. We have shown here that growth
rate of cells with serum was twice as fast as that of cells without serum. In this case, even
though arsenic and cadmium are not genotoxic, many studies suggest that eventually
these chemicals damage to gene indirectly if transformational phenomena are irreversible.
The short term exposure to low levels of these chemicals does not induce transformation.
Even though it might show some morphological changes, the cells return to normal when
the carcinogen is removed. The UROtsa cells with serum undergo twice as much cell
division as cells without serum. Due to increased cell cycle events, cells may be more
susceptible to indirect genetic damage by arsenic or cadmium and it may increase chance
of aggressive malignancy. The second possibility is due to differences cell culture
medium composition. The serum-free medium has very restricted nutrients and trace
elements. The serum-free medium in this study contains Dulbecco’s modified Eagles’
medium and Ham’s F-12 supplemented with selenium, insulin, transferrin,
hydrocortisone, triiodothyronine and epidermal growth factor. Otherwise, serum
containing medium is composed of Dulbecco’s modified Eagles’ medium and bovine
serum. Any compound that exists in serum-free medium but not in serum containing
medium may delay the onset of tumorigenesis indirectly. The third possibility is that
extracellular matrix proteins or cell-cell adhesion proteins may delay transformation of
UROtsa cells in serum-free medium. Under serum-free cell culture medium, confluent
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UROtsa cells produced three-dimensional structures (21). The cells displayed numerous
desmosomal connections, complex interactions of the lateral membranes, and abundant
intermediate filaments within the cytoplasm. Freeze fracture analysis also demonstrated
that the cells possessed tight-junction sealing strands and gap junction. The overall
morphology was most consistent with that found in the intermediate layers of in situ
urothelium. Different expression patterns of cell adhesion proteins including integrins, âcatenin and cadherin in transformed cells have been reported (26). Reduced expression of
E-cadherin has been associated with increased tumor recurrence and invasiveness and
decreased overall survival of bladder patients (27, 28). The presence of multiple
abnormalitiese in the E-cadherin-catenin complex has been correlated with advanced
tumor stage in bladder cancer (29). The morphological change of cells is one of the
characteristics of transformation when cells are exposed to carcinogens. Several studies
have demonstrated morphological changes associated with transformed cells exposed to
carcinogens or transfected by genes that are important in transformational processes (30).
Several transformed cells formed morphologically different types of foci (31). In this
study, we showed no morphological change in UROtsa cells after arsenic or
cadmiuminduced transformation. Morphological studies have shown a correlation
between loss of E-cadherin and expression and tumor cell invasion and metastasis (32).
The cell adhesion proteins and several extracellular matrix proteins might be considered
as tumor suppression proteins (33). It is also reported that the behavior of non-malignant
bladder cells differ significantly from that of cancer ones with respect to the integrins
used as well as the participation of glycosylation in adhesion (34). The integrin α6β4 with
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collagen VII is not lost in on the urothelium’s basement membrane forming a
hemidesmosomal anchoring complex, an effective barrier to cell migration. The
association of integrin with collagen VII is lost in bladder cancer (35). There may be
another possibility that extracelluar matrix proteins or cell-cell adhesion proteins may be
involved in tumorigenesis of UROtsa cells with serum-free medium.
The metallothionein (MT) is a small protein with high binding affinity with
various metals and induced by various agents. Most studies on MTs have focused on
essential trace element homeostasis and heavy metal detoxification. Recently, the role of
MTs in carcinogenesis has become prominent due to their linkage with drug resistance
(36). Recent studies report nuclear localization of MT protein during S phase of cell cycle
and malignant cells (37). Several studies have demonstrated a correlative relationship
between overexpressed MT and failure of chemotherapies (38). There is ample evidence
showing that overexpression of metallothionein-3 is linked to certain tumors including
breast and bladder cancer (39, 40). The MT-3 exhibits distinct properties from MT-1 and
MT-2 in several ways. Several studies have demonstrated that the expression of MT-3
(but not MT-1) inhibits the growth of cultured cells (41). MT-3, but not MT-1 or MT-2
protein also inhibits the survival of neurons cultured with brain extracts from people with
Alzheimer’s disease (42). The increased expression of MT-1 was not sufficient to rescue
the pancreatic acinar cells from the lethal effects of MT-3 overexpression (43). Heavy
metals and other agents that can induce MT-1 and MT-2 protein do not induce MT-3.
Selection of tissue cells for resistance to heavy metals results in elevated levels of MT1/2 protein by amplification of the entire MT gene locus (44). This study supports that
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MT-1 and MT-2 proteins were induced dramatically by exposure to arsenic or cadmium
but not MT-3 protein. This study also suggests that the increased MT-1 and 2 proteins
may be not involved in the initiation of transformational steps because there was no
significant difference in induction levels of MT by cadmium between serum and
serumfree medium. This result supports other studies that levels of MT protein are
usually undetectable in low grade tumors and increased with several high-grade in tumors
(45, 46).
Bladder cancer is one of the few tumors in which occupational and environmental
exposure is considered to be a major risk factor. This study reports in vitro transformation
of nontumorigenic human urothelial cell line UROtsa by chronic exposure to low
concentrations of arsenic and cadmium. The arsenic- or cadmium-transformed cells
exhibited anchorage-independent growth. There was no significant difference in
tumorigenic ability or other characteristics between arsenic and cadmium-induced
transformation. However, there was a significant difference in tumorigenicity between
cells in serum and serum-free medium. Due to the three-dimensional structure of UROtsa
cell line under serum-free medium, this in vitro transformation model system will be
useful not only in investigations on the mechanisms of arsenic- or cadmium- induced
carcinogenesis of bladder cancer but also to study possible roles of extracellular matrix
proteins and cell-cell adhesion on the progress of bladder tumor.
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Tumorigenicity and Histological Observation of Tumors Produced by
Arsenic- or Cadmium-Transformed Cells in Nude Mouse
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Introduction
Human urinary bladder cancer is the fourth most common form of cancer among
men and eighth among women (1). Bladder cancer is one of tumors in which
occupational and environmental exposure to chemicals have been documented as major
risk factors. Carcinogens derived from occupational exposures, cigarette smoking,
recurrent inflammatory conditions and schistosomal infections are important factors for
initiation of bladder cancer (2). Although most bladder cancers initially were diagnosed
as superficial papillary transitional cell carcinomas with relatively benign condition, 15%
of diagnosed patients went through progression to deep muscle invasion of superficial
bladder tumor due to high recurrent rates (3).
Based on epidemiological and animal studies, arsenic and cadmium are
considered as human carcinogens, although the molecular mechanisms are still unclear
(4,5). The development of model system for in vitro transformation of human bladder cell
line by exposure to arsenic or cadmium is important to understand molecular mechanisms
of bladder tumors by these carcinogens. Urothelium is a highly specialized tissue lining
the mammalian urinary tract, and is described as a transitional epithelium. Ninty percent
of bladder cancer is due to malignant transformation of these transitional epithelial cells.
In the previous study, we showed chronic exposure of low concentration of arsenic or
cadmium resulted in malignant transformation of human urothelial cell line, UROtsa,
based on increased growth rate and anchorage-independent growth in soft agar. In the
present study, we examined the tumorigenicity of these transformed UROtsa cells.
Tumorigenicity Assay
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UROtsa cells exposed for seven months to 1 µM arsenic or 1 µM cadmium
UROtsa cells with and without serum were used to test capability of tumor development
after injection into nude mouse. Figure 19 demonstrates the results of a representative
experiment with NCr-nu/nu mice and the efficiency of tumor formation calculated from
all of the experiments. The untreated UROtsa cells and PC-3 cells were used for negative
and positive controls, respectively. Tumors arose in 10 out of 11 mice injected PC-3 cells
while none of the untreated UROtsa cells gave rise to tumors in any mouse. All
transformed UROtsa cells were capable of forming tumors within 1 week after injection
into the athymic nude mice. The arsenic or cadmium- transformed cells with serum
formed tumors 10 out of 10, and 10 out of 11 inoculated mice, respectively. The arsenic
or cadmium- transformed cells without serum formed tumors 5 from 9, and 7 from 10
inoculated mice, respectively. Although the frequency of colony formation of
transformed cells without serum in soft agar was lower than that of transformed cells with
serum, the tumor incidence in nude mice was not significantly different (Table 2).
Histology of nude mouse tumors produced by cadmium-transformed cells
Tumor tissues of nude mouse produced by transformed UROtsa cells from 5-9
weeks after injection were fixed in 10% neutral formalin and processed for paraffin
embedding. There was no tumor metastasis because the border between tumors and
surrounding tissues was clearly delineated. The tumors formed by the cadmium
transformed UROtsa cells with serum were composed of infiltrating nests and masses of
moderately differentiated cells (Fig 20A). These infiltrating tumor nests and masses
demonstrated increased differentiation from the basal surface with was composed of
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Fig. 19 Tumorigenicity of arsenic or cadmium exposed UROtsa cells in nude mice.
UROtsa cells treated with 1 µM arsenic or cadmium for seven months were inoculated
subcutaneously into nude mice (n = 9 -11).Tumor incidence data as a percentage of the
number of mice inoculated was collected 5 weeks after injection. The sAs and sCd
represent that UROtsa cells in arsenic and cadmium in serum medium, respectively. The
fAs and fCd represent that UROtsa cells in arsenic and cadmium in serum-free medium.
The untreated PC-3, prostate cancer cell line, was used for positive control.
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Table 2 Tumorigenicity of arsenic or cadmium exposed UROtsa cells in nude mice.
UROtsa cells treated 1µM arsenic or cadmium for seven months were inoculated
subcutaneously into nude mice (n = 9 -11).Tumor incidence data as a percentage of the
number of mice inoculated was collected 5 weeks after injection.
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Fig 20. Histological analysis of tumors produced by heterotransplatation of
cadmium-transformed UROtsa cells with serum into nude mice.
General view of H & E stained tissues from tumor derived by inoculated cadmium –
transformed cells.
(A) Nests and cords of infiltrating cells with centrally located, large, eosinophilic cells
and focal central necrosis. The tumor sample was shown at the 7 weeks of injection with
40 x of magnification. (B) Eosinophilic, filamentous cytoplasmic accumulation s in cells.
The shown tumor tissue was taken picture at 400 x magnification at the 7 week of stage
after injection. (C) Calcium deposits in areas of central necrosis within tumor nests. The
shown tumor tissue was at 200x magnification at the 9 week of stage after injection.
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small compact cells. Larger, more differentiated cells, characterized by an eosinophilic
cytoplasm and a distinct cell border were present towards the center of these tumor
masses (Fig 20A). These more differentiated cells were very common and most contained
eosinophilic filamentous material which was often swirled within the individual cells (Fig
20B). Areas of necrosis were rare even within the largest tumor specimens, but when
present often contained prominent calcification admixed with eosinophilic laminations
within the central necrotic areas (Fig 20C). The tumors formed by cadmium-transformed
UROtsa cells without serum formed smaller tumors in the nude mice and were composed
mainly of tight nests of moderately differentiated cells (Fig 21A). The tumors formed
tight nests and whorls with little tendency for differentiation towards the center of the
mass and there was also very little tendency for central necrosis or deposit within cells
(Fig 21A). Although cells could be found that demonstrated differentiation towards the
central areas of the whorls, this was not as prominent as found for tumors by transformed
cells with serum, and many areas of the tumor had minimal tendency for this phenotypic
squamoid differentiation ( Fig 21B). There was a slight increase in nuclear pleomorphism
as noted by vesicular nuclei, nuclear lobulations and occasional nucleoli (Fig 21B, C).
Histology of nude mouse tumors produced by arsenic-transformed cells
The tumors formed by arsenic-transformed UROtsa cells with serum were
remarkable for the phenotype of squamoud differentiation. Tumor sheets and nests
demonstrated large central areas of acellular, esosinophilic, concentrically laminated
deposits resembling the keratin ‘pearls’ of squamous cell carcinoma (Fig 22A,B). The
uppermost layers of neoplastic cells, just underneath the acellular deposits, contained
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Fig 21. Histological analysis of tumors produced by heterotransplatation of
cadmium-transformed UROtsa cells without serum into nude mice.
General view of H & E stained tissues from tumor developed by cadmium-transformed
UROtsa cells cultured in serum-free medium.
(A) Small compact nests of cells lacking the central necrosis were shown at 100x
magnification of 6week stage of injection. (B) A rare focal showing squamoid phenotypic
change at 400x magnification of 6 week of stage after injection. (C) Mild to moderated
nuclear pleomorphism was shown at 400 x magnification at the 6 week after injection.

97

(A)

(B)

(C)

(D)

(E)

98

Fig 22. Histology (H&E staining) of tumors produced by heterotransplantation of
arsenic-transformed UROtsa cells with serum into nude mice. (A) Typical area of a
tumor heterotransplant showing large squamous change (25 x) at the 9 week stage of
injection. ( B) Squamous features with a central “pearl” of acellular, concentric deposits
(200 x) at the 9 week of stage after injection. (C) Cells recapitulating granular cell layer
of squamous epithelial with basophilic keratohyaline and a centrally located laminated
“pearl” (400 x), 9 week stage. (D) Cells with intracellular bridges recapitulating the
“spiny” layer in squamous epithelium (400 x), 5 week stage. (E) Intracellular bridging
between cells (800 x), 5 week stage.

99

punctuate basophilic granules resembling the keratohyaline seen in the granular layer of
the skin epidermis (Fig 22C). Also recapitulating the squamous differentiation, neoplastic
cells between this and the basal layer of cells demonstrated prominent intracellular
connections (Fig 22D, E), similar to the granulose or spinous cells within the skin. The
tumor cells displayed moderate nuclear pleomorphism with irregular nuclear contours,
grooves, and chromatin distribution with occasional prominent nucleoli. The morphology
of the tumors formed by arsenic-transformed UROtsa cells without serum was similar to
those grown on serum-containing growth medium (Fig 23A). These tumors exhibited
more pleomorphism although the squamous features could still be easily discerned (Fig
23A). Nuclear features were more pleomorphic with prominent nucleoli and occasional
multinuclear giant cells (Fig 23B).
Histology of nude mouse tumors produced by human prostate cancers was
examined. Tumors from nude mice with inoculation of human prostate cancer cell line,
PC-3, showed less differentiated condition. Tumors were composed of sheets of
undifferentiated cells without whorls or nests of squamous or transitional cell
differentiation (Fig 24A, B). No intracellular bridges, acellular deposits or spinous
processes were observed. There was moderate pleomorphism in both the cells and nuclei.
Foci of necrosis were scattered throughout the cellular sheet.
Discussion
There is extensive epidemiologic evidence that trivalent and pentavalent forms of
arsenic cause characteristic skin alterations, including hyperkeratosis and skin cancer in
humans (6). Epidemiologic studies have shown a strong association between arsenic
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Fig 23. Histology of tumors produced by heterotransplantation of arsenictransformed UROtsa cells without serum into nude mice. Histological results from 9
week- tumor tissues after H & E stain. (A) Squamous changes in poorly formed whorls at
200 x magnifications. (B) Nuclear pleomorphism and tumor giant cells at 630 x
magnifications.

Fig 24. Histology of tumors produced by human prostate cells injected nude mice.
The human prostate cells, PC-3, were injected into nude mice. After 5 weeks later, mice
were sacrificed and tumor tissues were removed, fixed in neutral formalin, embedded in
paraffin, sectioned at 5µm, and stained with H & E stain. (A) and ( B) showed that
tumors were composed of undifferentiated cells without whorls or nests of squamous or
transitional cell differentiation.
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ingestion from contaminated drinking water and the development of bladder cancers in
Taiwan, Argentina, Chile, and Japan (7-10). Combined in vitro transformation and nude
mouse tumorigenicity studies will be helpful in understanding the carcinogenic potential
of environmentally and occupationally related agents (11).
In this study, we showed tumorigenicity of arsenic or cadmium-transformed
human urothelial cell line. Tumorigenic animal cells injected subcutaneously into nude
mice produce well-defined and frequently encapsulated tumors at the site of injection.
Examination of histological sections of tumors that develop after the injection of
tumorigenic animal cells into nude mice confirms the well-circumscribed nature of the
growing tumor. In addition, tumors that develop in nude mice after transplantation of
malignant tumor cells retain the original tumor histopathology in the nude host. Tumors
that grew in the nude mouse after heterotransplantation of human adenocarcinomas still
resembled the original adenocarcinomas histologically (12). A unique finding in the
present study was the morphology of the tumors produced by the heterotransplantation of
the arsenic-transformed UROtsa cells into nude mouse. In the general population, the
overwhelming majority of bladder cancers are transitional cell carcinomas with little or
no evidence of squamous differentiation. In contrast, the tumor heterotransplants formed
by the arsenic-transformed UROtsa cells displayed dominant features of squamous
differentiation. These features include: concentrically laminated deposits resembling
keratin “pearls”; granules resembling the keratohyaline seen in the granular layer of the
skin epidermis; and, cells with predominant intracellular connections similar to the
granulosa or spinous cells within the skin. It is possible that the squamous differentiation
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may be an artifact of the model system or it may be a real feature to be expected in
bladder cancers that arise from urothelial cells experiencing a long-term, substantial
exposure to arsenic. The best answer to this question would be a study detailing the type
of bladder cancers produced by patients in areas where there are high concentrations of
arsenic in the drinking water. There is indirect evidence to suggest that the feature of
squamous differentiation is a legitimate property of the urothelium transformed by
longterm exposure to arsenic. The most compelling evidence is that a hallmark of high
level environmental arsenic exposure is hyperkeratosis and skin cancer (13,14). Therefore,
it would not be surprising if the keratinocyte-like cells of the bladder reacted to arsenic
similar to that found for skin keratocytes. Specificity for arsenic is also suggested by the
finding that malignant transformation of the UROtsa cells with cadmium resulted in
tumor heterotransplants with minimal evidence of squamous differentiation. If the
squamous differentiation was an artifact, it would be expected that a similar treatment
protocol with cadmium would have produced similar results regarding squamous
differentiation of the heterotransplants; however, only very rare profiles of squamous
change were detected in the cadmium-induced tumors. That the squamous differentiation
was not a rare one-time event is suggested by the finding that arsenic-exposed UROtsa
cells grown on serum-containing and serum-free media both produced tumors with
squamous differentiation when heterotransplanted into nude mice. These results suggest
that bladder tumors diagnosed in areas where there exist high concentrations of arsenic in
the drinking water should be examined carefully for features of squamous differentiation.
There is only one other study of successful malignant transformation of human
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epithelial cells with arsenic in immortalized epithelial cell culture, RWPE-1, derived
from the prostate gland (15). The RWPE-1 cells were malignantly transformed when
exposed to 5 µM sodium arsenite for 29 weeks. The resulting cultures formed epithelial
tumors when heterotransplanted into nude mice. These tumors were positive for the
production of prostate specific antigen, but displayed neither features of squamous
differentiation nor keratinocyte differentiation. There were several interesting differences
between the studies in the RWPE-1 and UROtsa cells. The RWPE-1 cells were exposed
to 5µM arsenite for 29 weeks, a concentration which causes no noticeable cell mortality.
The malignantly transformed cells were identified by the formation of foci of cells that
had lost contact inhibition of growth. When these cells were heterotransplanted into nude
mice, invasive tumors formed as noted by invasion of the underlying muscle layers. In
contrast, the UROtsa cells experienced over 95 % cell death when treated with 5-fold less
concentration of arsenic, and the malignantly transformed cells arose from clones that
survived this initial arsenic-induced toxicity. Cultures arising from these clones had
highly elevated growth rates but did not form foci of cells indicative of a loss of contact
inhibition in cell culture medium even though they showed anchorage-independent
growth in soft agar. When these cells were heterotransplanted into nude mice, tumors
formed but did not invade the underlying muscles layer of the mouse. Thus, the UROtsa
cells were more sensitive to arsenic toxicity than the RWPE-1cells, but the malignantly
transformed RWPE-1 cells formed a more aggressive tumor.
The present study also demonstrates the cadmium-induced malignant
transformation of human urothelial cells. This is a significant finding since cadmium is
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classified as a human carcinogen with the potential for implication as a bladder
carcinogen; although the data is less extensive than that linking arsenic as a bladder
carcinogen (16, 17). The present malignant transformation of human urothelial cells by
cadmium presents compelling evidence that cadmium has the potential of being a human
bladder carcinogen. Furthermore, the model system developed should provide a valuable
set of human cell lines to study the development and progression of cadmium-induced
bladder cancer. The tumor heterotransplants produced by the cadmium-transformed cells
were epithelial in character and had features consistant with those expected of an
undifferentiated transitional cell carcinoma of the bladder. An additional significant
finding is that there is evidence that the level of cadmium required to malignant
transformation of urothelial cells is quite low when compared to the prostate, an organ
where there is substantial evidence for a role of cadmium as a prostate carcinogen (18,
19). The concentration of cadmium in the prostate of people with no known occupational
exposure to cadmium is between 11 and 28 µM (20, 21). The studies demonstrating the
cadmium-induced malignant transformation of human prostate epithelial cells showed
that 10 µM of cadmium induced transformation following 8 weeks of continuous
exposure to the metal (20). This level of cadmium exposure was not noted to be lethal to
the cells. In comparison, the UROtsa cells were malignantly transformed at a 10-fold
lower cadmium concentration and this concentration produced significant cytotoxicity to
the cells. This provides indirect evidence that human bladder urothelium might be
susceptible to relatively low concentration of cadmium.
Several studies demonstrate a lack of correlation between tumorigenic
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transformation and increased colony formation efficiency, or cell growth rate. The
morphological alternation may not be necessary in malignant transformation (22). Some
anchorage-independent cells are not tumorigenic in nude mice, but almost all of the
tumorigenic cells show anchorage-independent growth in vitro. These data suggest that
the acquisition of anchorage-independent proliferation in vitro is a necessary but not
sufficient for tumorigenicity. Malignancy of cultured cells is demonstrated convincingly
by the tumorigenicity of cells when transplanted into athymic nude mice. In this study,
we have showed that in vitro transformed UROtsa cells by exposure to arsenic or
cadmium formed tumors after injection into nude mice. The tumors generated in this
study showed diversity, even though these were generated from arsenic- or cadmiumtransformed UROtsa cells. These data demonstrate the capability of a human epithelial
cell type to give rise to different histological phenotypes during tumorigenesis.
During tumorigenesis, different genes are turned off and on, and these phenomena
differ from cell types and tumor types. Therefore, these characteristic genes and proteins
can be used as markers for specific cancers and many clinical trials are being performed
to identify specific markers. Effort is being made to find specific markers between benign
and neoplastic cells because it will make it easier to detect cancer earlier and provide
better treatment for patients. Recent studies suggest several molecules as possible
molecular markers for bladder cancer. There are, however, no widely accepted tumor
markers that allow widespread screening for the early presence of bladder cancer or for
the detection and monitoring of advanced stages of this disease (23). In this study, we
showed the arsenic-induced malignant transformation of human urothelial cells. The
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finding that human urothelial cells are directly susceptible to the transforming effects of
inorganic arsenite is biologically significant because the study of arsenic-induced bladder
carcinogenesis has been hampered by the lack of suitable animal models, since arsenic
induced tumors in rodents have been difficult to produce unless arsenic is combined with
other agents. The cell lines and heterotransplants developed in the present study are also
significant as a model system on which to base studies defining the molecular and genetic
events associated with arsenic-induced bladder cancer. Thus, the current model system
consisting of the original non-tumorigenic UROtsa parental cell line, the arsenic-induced
malignant transformants, and derived tumor heterotransplants should provide a valuable
system to study the development and progression of arsenic-induced bladder cancer.
In the previous study, we showed the malignant transformation of normal human
urothelial cell line by chronic exposure to cadmium or arsenic in vitro. As demonstrated
in this study, the malignant transformation of these cells was confirmed by the
development of tumors after inoculation of these cells into nude mice. Malignant
transformation of normal human urothelial cells is compelling evidence that arsenic and
cadmium have the potential to be human bladder carcinogens.
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